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This dissertation reports the development of novel targeted contrast agents based
on gold nanorods (GNRs) and their application in imaging cancer cells, cardiovascu-
lar inflammatory diseases and drug delivery monitoring using photoacoustic imaging
(PAI). The GNRs based contrast agents were imaged with high signal-to-noise ratio
(∼17) and excellent spatial resolution (∼250 µm) with concentration down to 10 pM
in biological tissues. The inherent disadvantage of limited imaging depth (∼5 mm
from skin surface) in PAI due to strong attenuation of light in biological tissues re-
stricts the monitoring of drug delivery in intra-articular connective tissues. A novel
targeted optical and nuclear dual-modality contrast agent was successfully developed
by radiolabeling GNRs with 125I to monitor anti-rheumatic drug delivery. PAI and
nuclear imaging in combination present the detailed distribution of GNRs conjugated
anti-rheumatic agent in intra-articular connective tissues with concentration down to
10 pM and radioactive label of 5 µCi . Radiolabeled contrast agents were further con-
jugated with polyethylene glycol (PEG) to increase the in vivo circulation time and
prevent rapid clearance through accumulation into liver. Addition of PEG molecules
on the surface of contrast agent increased the in vivo circulation time from 4 minutes
to over 4 hours allowing specific targeting by the contrast agent.
Apart from application as a contrast agent, gold nanorods due to their anisotropic
shape also form interesting building blocks for 3D superstructures with wide range
of optical properties for applications in plasmonics, metamaterials and sensors. Un-
der controlled evaporation monodisperse GNRs were self-assembled into micron sized
xiv
three dimensional supercrystals. The highly organized supercrystals of GNRs with
plasmonic antennae enhancement of electrical field have made possible the first real-
time detection of prions (concentration down to 10−10 M) in complex biological media
such as serum using surface enhanced raman scattering. CdTe nanoparticle-GNRs su-
perstructures were made through biotin-streptavidin specific binding and investigated
as potential gain materials for overcoming metallic losses in metamaterials through
exciton-plasmon coupling. An extremely simple technique was developed to transfer
gold nanorods from aqueous to organic medium, which allowed orientational order-
ing of low aspect ratio rods in dispersion through application of high electric fields.
Alignment of non-aqueous GNRs in dispersion was achieved with a maximum order
parameter of S≈0.9. The key results reported in this report are anticipated to lead
to the development of novel, sophisticated, multifunctional contrast agents which can
recognize specific receptors, deliver drugs to targeted tissue, aid in reporting outcome
of therapy, provide real-time assessment of therapeutic efficacy, and most importantly,
monitor intracellular changes to help understand pathological mechanisms. The novel
superstructures reported with GNRs in various spatial arrangements are anticipated





Nanotechnology is the science of controlling matter at the atomic or molecular
scale. In the past decade major advances have been made in the synthesis of nanopar-
ticles (NPs) of various size, shape and composition with high degree of monodisper-
sity. However applications in imaging, plasmonics and metamaterials1–4 require a
substantial progress in engineering multifunctional NP surfaces as well as assembly
of individual nanoparticles into complex 3D geometries. The optical and magnetic
responses of an ensemble of NPs are dramatically different compared to the individ-
ual NPs due to collective resonance of free electrons on the surface. Hence a very
high degree of control over spatial organization is required to assemble and arrange
the nanoparticles into various configurations to achieve desired optical response from
the material. Functionalizing NP surfaces with various biomolecules, polymers and
surfactants is a key step towards fine tuning various forces acting upon the NPs
that eventually lead to organized superstructures. This dissertation reports novel
developments in engineering functional metallic nanoparticles and their application
in molecular imaging, diagnostics and optical metamaterials.
The emergence of “molecular imaging” as an integrated discipline in medicine has
set the stage for an evolutionary leap in diagnostic imaging and therapeutic monitor-
ing. Molecular imaging makes molecular processes visible, quantifiable, and trackable
1
over time in a live animal or human, in physiologically authentic environments. In
the preclinical stages, molecular imaging reduces the number of experimental animals
that need to be sacrificed because data is generated noninvasively. In clinical practice,
molecular imaging may help with the decision to take, or not take, a drug candidate
into clinical trials and will offer another way to monitor efficacy once a drug is in tri-
als. Molecular imaging involves integrating new imaging technology with new imaging
agents. The coincident expansion of nanotechnology, which can significantly acceler-
ate the development of new imaging agents, has already played a fundamental role
not only in molecular imaging, but also in biosensors, biomarkers, and drug delivery.5
This area of research is anticipated to lead to the development of novel, sophisticated,
multifunctional applications which can recognize specific receptors, deliver drugs to
targeted tissue, aid in reporting outcome of therapy, provide real-time assessment
of therapeutic efficacy, and most importantly, monitor intracellular changes to help
understand pathological mechanisms.
Photoacoustic tomography or Photoacoustic Imaging (PAI), also referred to as op-
toacoustic tomography or thermoacoustic tomography, is an emerging hybrid molec-
ular imaging modality that is non-invasive, non-ionizing, with high sensitivity, sat-
isfactory imaging depth and good temporal and spatial resolution.6–18 In SPAT, a
short-pulsed laser source is used to illuminate the tissue sample and generate pho-
toacoustic waves due to thermoelastic expansion. Then the signals are measured by
wide-band ultrasonic transducers to reconstruct the image of the sample. Therefore,
the contrast of PAI is based on the optical absorption in biological tissues, but its
resolution is not limited by optical diffusion or multiple photon scattering but in-
stead by the bandwidth of detected photoacoustic waves.19 Because ultrasonic waves
are much less scattered in biological tissues than light, PAI depicts subsurface joint
tissue structures much more accurately than optical imaging. In other words, PAI
overcomes the resolution disadvantage of optical imaging and the contrast disadvan-
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tage of ultrasound imaging. Moreover, like conventional optical technologies, PAI also
presents a unique ability in tracing optical contrast agents in biological tissues. The
application of PAI holds promise for evaluation at molecular or cellular level due to
the high sensitivity of PAI to a variety of extrinsic optical contrast agents. Monitoring
of drug delivery in experimental models and in human diseases would undoubtedly
be very helpful for both basic research and clinical management of diseases.
Several organic dyes and metallic NPs have been studied as PAI contrast agents
in the past decade. Wang et al have demonstrated enhanced photoacoustic signal
from Indocyanine Green (ICG), an FDA approved dye that absorbs light in the Near-
Infrared (NIR) region.20 Ashkenazi et al has developed ICG embedded ormosil par-
ticles conjugated with HER2 for targeted imaging of breast cancer cells.21 More
recently Song et al has used Methyline Blue as a contrast agent to detect sentinel
lymph node.22 In comparison with the contrast agents based on organic dyes, metallic
NPs could have better stability, less photo bleaching and greater flexibility of tuning
their optical spectra, although further investigation is necessary to reduce their toxi-
city before large scale clinical use can occur.23 Gold nanoparticles have particularly
been used as PAI contrast agents due to their exceptionally strong optical responses
in the visible and NIR spectral range.10,21,24–29 The combination of the unique op-
tical and biological properties of gold nanoparticles makes them a good choice for
optical contrast agent. PAI utilizes the strong optical absorption of gold nanoparti-
cles which is due to localized surface-plasmon resonance (LSPR). This is a classical
effect in which the electromagnetic field from the light source drives the collective
oscillations of free electrons of metallic nanoparticles into resonance. Typically, the
absorption cross section of a metal nanoparticle can be an order of magnitude larger
than its geometrical cross-sectional area.30 Employing laser-based PAI, the dynamic
distributions of gold nanoshells based contrast agents in small-animal brains have
been imaged with both high spatial resolution and satisfactory sensitivity.20,31 Yang
3
et al has studied gold nanocages to evaluate the cerebral vortex in rats.32 Other
than performing as contrast agents for imaging, gold NPs have also been widely used
as vehicles to achieve drug delivery and agents for photothermal therapeutics.33–35
Most of reports in literature that have explored metallic NP as contrast agents for
the enhancement of PAI sensitivity are generic in nature, lacking specific targeting of
tumor cells or inflammatory regions of interest.
Gold Nanorods (GNRs) are a unique kind of gold nanoparticles because of their
shape anisotropy, sharp resonances in optical regime and the irrelatively small size,
with their diameters approaching the molecular scale. GNRs due to anisotropy in
shape have two plasmon resonance peaks, smaller peak in the 500 nm range due to
the plasmon oscillation perpendicular to the axis of the rod, while the strong NIR
peak, which is tunable by varying the nanorod aspect ratio, originates from the lon-
gitudinal oscillations of plasmons along the main axis. Since NIR light transmits
through tissue more efficiently than visible light, the additional plasmon resonance
makes nanorods promising candidates for in vivo diagnostic and therapeutic applica-
tions. This research reports the development of novel GNRs based targeted contrast
agents, studied extensively for inflammatory response imaging, tumor imaging and
monitoring anti-rheumatic drug delivery (Chapter II&III).36–38
Despite the variety and relative effectiveness of PAI contrast agents available, there
is an inherent disadvantage in PAI measurements due to the strong attenuation of
light in biological tissues as well as the high background signal as a result of intrinsic
tissue optical absorption. PAI presents local spatial resolution on the sub-millimeter
level however the penetration depth limits its ability to make measurements with
satisfactory signal-to-noise ratio deep inside the tissue. In fact, the same problem is
present for all nanoparticle contrast agents based on optical emission, which became
increasingly popular recently. This inherent problem of light emission can be overcome
indirectly by merging it with another imaging modality which can provide high signal-
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to-noise ratio even deep inside the tissue and assist to validate the findings of the other
technique. The intrinsic disadvantage of limited imaging depth in PAI was overcome
by designing radiolabeled targeted contrast agent based on GNRs, to merge PAI with
nuclear imaging (Chapter IV). Moreover, by covalent binding of radioisotopes on the
surface of targeted GNRs, nuclear imaging such as PET and SPECT can for the first
time image the concentration and distribution of gold NP based agents in vivo, which
could contribute considerably to understanding of the toxicity and pharmacokinetics
of any novel gold nanocolloids in the future (Chapter V).
The idea of targeted contrast agents is extended to another form of widely used
clinical imaging technique, X-ray computed tomography (CT). CT is one of the most
useful diagnostic tools in hospitals today in terms of availability, efficiency, and cost.
Currently, CT is not a molecular imaging modality since relevant targeted and molec-
ularly specific contrast agents have not yet been developed. Present CT contrast
agents are predominantly based on iodine containing molecules, which are effective in
absorbing X-rays; however, they are nonspecifically targeted because they cannot be
conjugated to most biological components or cancer markers and they allow only very
short imaging times due to rapid clearance by the kidneys. Chapter VI demonstrates
the potential of targeted GNRs based contrast agents for molecular CT imaging.
Understanding and controlling the collective behavior of nanoparticles (NPs) is
a challenging problem of fundamental and practical importance.39 This is particu-
larly true for GNRs because their anisotropy implies additional functionality on the
scale of individual particles and their assemblies, enabling a variety of applications
from cloaking devices to biological sensing and solar energy conversion.40–45 One of
the most fascinating types of metamaterials that is actively researched is negative
refractive index materials (NIMs), which often requires GNRs assembled into various
configurations. Among other challenges, one of the major limitations of present day
NIMs is their large amount of energy dissipation which frustrates the restoration of
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near field modes. To take advantage of exciton-plasmon interactions, an optical sys-
tem consisting of semiconductor nanoparticles (NPs) and GNRs that can continuously
pump energy into the NIM resonator is described in Chapter VII. A key requirement
for realizing bulk optical NIMs is controlling orientational order of GNRs. However
due to the high dielectric constant of water, aqueous dispersion of low aspect ratio
GNRs cannot achieve good alignment upon application of electric field. Chapter VIII
describes a simple novel technique for transferring GNRs from aqueous to organic
solvents. Field induced orientational control of low aspect ratio GNRs dispersed in
toluene was achieved.
Under controlled evaporation individual GNRs were assembled into large 3D su-
percrystals with uniform hexagonal packing which due to nanoantenna phenomena
exhibits strong electric field enhancements in interstitial gaps. Chapter VIII describes
the detection of infectious prion proteins using the 3D GNRs supercrystal as surface
enhances raman scattering (SERS) substrate. CST MICROWAVE STUDIO simula-
tions are performed to investigate the nanoantenna phenomena. Chapter X concludes




Photoacoustic Imaging of Early Inflammatory
Response Using Gold Nanorods
2.1 Introduction
Excessive and uncontrolled inflammation plays a key role in a variety of sys-
temic diseases including rheumatoid arthritis (RA), systemic lupus erythematosus,
and allergic diseases and a key role in atherogenesis. Furthermore, patients with
diseases characterized by chronic systemic inflammation are at risk to develop accel-
erated atherosclerosis.46,47 Understanding the correlation between inflammation and
atherosclerosis may therefore provide prognostic information of considerable clinical
utility.48
Most myocardial infarctions occur when a plaque ruptures and a clot forms at the
site. Inflammation is believed to be a major factor in plaque rupture, and susceptible
plaques tend to have a damaged fibrous cap and numerous resident macrophages.
Inflammatory mediators promote the secretion of various collagenases, which erode
the fibrous cap and prevent its repair by smooth muscle cells. Blood that leaks
through the damaged cap coagulates quickly, aided by clot promoters produced by
T-lymphocytes and foam cells.49 Some biomarkers have predictive value for future
vascular events among apparently healthy subjects. Prospective epidemiological stud-
7
ies have found increased vascular risk in association with increased basal levels of
inflammatory cytokines such as interleukin-6 (IL-6)and tumor necrosis factor alpha
(TNF-α); cell adhesion molecules such as soluble or membrane-bound ICAM-1, P-
selectin, and E-selectin; and acute-phase reactants such as C-reactive protein and
fibrinogen. In this study, the adhesion molecule intercellular adhesion molecule-1
(ICAM-1) was chosen as a biomarker of inflammation and activation of endothelial
cells (ECs). ICAM-1 is also a strong inflammatory mediator in systemic inflammatory
diseases such as RA.50
Photoacoustic imaging (PAI) can be of exceptional value for detection of inflam-
mation and, in particular, the early forms of immune response. It uses rapid thermal
expansion induced by absorption of a laser pulse to create acoustic waves that can
propagate to a remote acoustic sensor. The distribution of optical absorption within
the object can be imaged by reconstructing the detected acoustic field.51 The contrast
of a photoacoustic image can be enhanced using external agents. Gold nanoparticles
conjugated with an antibody have been used to enhance optical absorption (and pho-
toacoustic signal) in targeted cancer tissue and provide high contrast for noninvasive
cancer imaging using PAI.21,52–54 In this study, a single layer of stimulated and un-
stimulated ECs labeled with bioconjugated gold nanorods (GNRs) were imaged using
PAI.
2.2 Experimental section
Human umbilical vein endothelial cells (HUVECs) were maintained on gelatin-
coated tissue culture plates in MCDB131 media (Gibco) supplemented with microvas-
cular EC growth factors (Cambrex). Cells were split into a six well plate (0.1×106
cells/well, 38 mm in diameter) two days prior to an experiment. Media were changed
24 h after splitting and the cells were left unstimulated or stimulated with the proin-
flammatory cytokines Interferon-gamma (IFN-γ) (200 ng/mL, Peprotech) and TNF-α
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(25 ng/mL, Peprotech) for 16 h. For photoacoustic and fluorescence microscopy mea-
surements, the HUVEC monolayer was washed with cold MCDB131 media. Cells
were blocked for 30 min at 4  in blocking media [MCDB131 1% bovine serum albu-
min(BSA) 1% horse serum(HS)]; the blocking solution was removed and the cells were
incubated for 1 h at 4  with GNR-conjugated anti-ICAM-1 (Biolegend) or isotype
control antibody and diluted fivefold with blocking media. The staining solution was
removed and the cells were washed with MCDB131. Monolayers were fixed in 4%
paraformaldehye in phosphate-buffered saline PBS for 1 h at room temperature, then
washed and stored in PBS at 4 . To confirm ICAM-1 expression in HUVECs, cells
were counterstained for 1 h at room temperature with a fluorescein isothiocyanate
FITC-conjugated goat antimouse IgG anti-serum 0.5 µg/mL in PBS/1% BSA/1%
HS, and the nuclei stained with Hoescht 33342.
Figure 2.1: Microscope images of (A) stimulated and (B) unstimulated ECs. Fluores-
cence images of (C) stimulated and (D) unstimulated ECs. ICAM-1 is shown in green
and nuclei are in blue. Immunofluorescent measurements were also performed using
a flow cytometer (E). ICAM-1 expression reflects that the ECs are well stimulated
(red solid line)
Fluorescence microscopy was performed using a Leica inverted microscope and
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acquired images analyzed using ABODE PHOTOSHOP (Fig. 2.1). All images were
acquired and processed using identical settings. From the same batch, a well of
unstimulated or stimulated HUVECs was detached from the plate using trypsin,
ethylenediaminetetra-acetic-acid(EDTA) solution, incubated for 0.5 h on ice in block-
ing media, and labeled with unconjugated anti-ICAM-1 or isotype control antibody
(1 µg/mL). Labeled HUVECs were washed with MCDB131 then incubated with a
FITC-conjugated goat antimouse IgG antiserum (0.5 µg/mL) in PBS. Levels and in-
tensity of ICAM-1 expression were measured using a Coulter Epics XL flow cytometer
and analyzed using WINMDI software (version 2.8) (Fig. 2.1).55,56
GNRs of aspect ratio of 3.5 were synthesized.57,58 Their optical absorption was
centered at 700 nm. Synthesized GNRs have a bilayer of surfactant hexadecyltrimethy-
lammonium bromide (CTAB) on their surface acting as a stabilizer to prevent aggre-
gation. After removing excess CTAB, the GNRs form a pellet at the bottom of the
tube, which was redispersed in de-ionized water. A layer of Polyacrylic acid (PAA) is
absorbed on the surface of GNRs by adding 1.5 mL of 1 mg/mL PAA solution to 1 mL
of GNRs solution. Excess PAA in solution was removed by centrifugation and redis-
persion. The layer of PAA provides the -COOH functional group required for conjuga-
tion. PAA-coated nanorods were dispersed in 1 mL of PBS 6.0 buffer solution followed
by the addition of 100 µL of 0.2 M (N-ethyl-N
′
-(3-dimethylaminopropyl)carbodiimide)
EDC and 100 µL of 0.2 M (N-hydroxy-succinimide) NHS.59–62 After 20 min, the re-
action mixture was added to 20 µL of antihuman ICAM-1 or mouse IgG2a. The
EDC/NHS mixture forms an active ester intermediate with the GNRs which under-
goes amidation reaction with the -NH2 group in the anti-ICAM-1 or IgG2a to yield
the conjugate. The reaction mixture was refrigerated overnight after removing the
unconjugated antibody.
Unstimulated or stimulated ECs were incubated with GNRs conjugated to anti-
ICAM-1. Additional wells were incubated with GNRs alone with no antibody con-
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Figure 2.2: Photoacoustic imaging setup
jugation (blank nanorods). These wells serve as controls to estimate nonspecific
binding levels of GNRs to cells. The concentration of the GNRs solution was 1012
particles/mL (103 particles/pL) for every case. The plate was then placed in the sam-
ple holder of the photoacoustic scanning setup depicted in Fig. 2.2. A pulse doubled
neodymium doped yttrium aluminum garnet laser (Surelite I-20, Continuum, Santa
Clara, CA) pumps an optical parametric oscillator (Surelite OPO Plus, Continuum)
to generate 5 ns pulses at 20 Hz with 12 mJ pulse energy. The wavelength was tuned
to 700 nm. The laser beam was directed to illuminate from the bottom of the cell
culturing well (approximately 4 mJ/cm2 fluence). A focused ultrasonic transducer
(LiNbO3, 50 MHz, f/1.5) is used to detect the photoacoustic signal. A motorized X-
Y stage was used to map the photoacoustic signal. For the map of cells bound with
bioconjugated nanorods, the step size was 50 µm and the step size was 250 µm for
the scan of cells bound with blank nanorods. The photoacoustic signal was averaged
eight times at each scanning grid point. The transducer output was amplified (model
5910PR, Panametrics), digitized, and recorded by a digital oscilloscope (WaveSurfer
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432, LeCroy Corp. Chestnut Ridge, NY) synchronized to the laser.
Figure 2.3: Photoacoustic images of (A) stimulated and (B) unstimulated ECs bound
with bioconjugated GNRs, and (C) stimulated and (D) unstimulated ECs bound with
blank GNRs. Note the scanning step was 50 µm for (A) and (B) and 250 µm for (C)
and (D). Fluorescence images of the same ECs used for photoacoustic studies were
also taken. The brightness of the fluorescent images differentiate (E) stimulated cell
from (F) unstimulated cells and match well to the photoacoustic images (A) and (B).
Images were taken over a 250×500 µm2 around of the center of the photoacoustic
images
2.3 Results and Discussion
Photoacoustic images are presented in Fig. 2.3. Photoacoustic intensity from the
bioconjugated nano rods bound to stimulated cells was 10 dB higher on average than
that from unstimulated cells. The photoacoustic intensity was also uniform over an
extended scanning region of 2×2 mm2. Scanned images at three different spots in the
same well result in approximately the same average intensity and were uniform. The
photoacoustic intensity from both stimulated and unstimulated cells bound with blank
nanorods was insignificant compared to that from cells with bioconjugated nanorods.
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This reflects very low nonspecific binding efficiency of blank GNRs to endothelial
cells. The same ECs were then counterstained for 1 h at room temperature with
a FITC-conjugated goat antimouse IgG antiserum and nuclei stained with Hoechst
33342. Fluorescence microscopy was performed using identical settings used above
(Fig. 2.3).
The fluorescence intensity of the images differentiate stimulated from unstimu-
lated cells and match well to the photoacoustic images presented in Fig. 2.3. Gold
conjugated isotype control antibody did not show induction of photoacoustic signal
upon HUVEC stimulation with TNF-α and (IFN-γ) (not shown), consistent with
previous measurements by fluorescence microscopy and flow cytometer shown in Fig.
2.1.
2.4 Conclusions
In summary, the feasibility of molecular imaging of inflammatory responses is
demonstrated. Bioconjugated gold nanorod contrast agents targeted stimulated ECs
overexpressing ICAM-1 and produced a high contrast for photoacoustic imaging.
These images clearly differentiate targeted inflamed cells from control unstimulated
ECs. In combination with a commercial ultrasound platform, photoacoustic molecu-
lar imaging using GNRs as contrast agents can detect inflammatory response at very
early stages in vitro and, potentially, in vivo. For in vivo applications, a proper laser
light delivery system synchronized to an ultrasound platform needs to be developed.
Minimum detectable gold nanorod concentration by a commercial ultrasound scanner
(Sonix RP, Ultrasonix, BC, Canada) was estimated to be about 1011 particles/mL
(102 particles/pL) in a gel phantom (agarose gel mixed with 5% intralipid). The
optical absorption coefficient at this concentration is about 0.7 cm−1. Early detection
of inflammation could lead to prompt identification and monitoring of many different
diseases. For applications in vascular diseases, light absorption by blood can be a
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potential problem. The aspect ratio selectivity of gold nanorod absorption spectra
will help this issue. In this study, the peak absorption was intentionally selected to
be 700 nm where absorption by blood is minimum (∼2 cm−1).63 At this wavelength,
light can be delivered to some of the major arteries such as the carotid. Based on
the absorption coefficient at minimum detectable concentration above, photoacoustic
intensity enhancement of 10 dB can be expected for gold nanorod concentration of
about 1.0×1012 particles/mL (1.0×103 particles/pL). This corresponds to only about
500 nanorods per EC of 10 µm in diameter (∼0.5 pL). In combination with an optical
fiber light delivery system, conventional intravascular ultrasound can also access some
other major arteries such as the coronary system.
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CHAPTER III
Photoacoustic Imaging of Joints Aided by an
Etanercept-Conjugated Gold Nanorod Contrast
Agent-an Ex Vivo Preliminary Rat Study
3.1 Introduction
TNF has been identified as a protein produced by the immune system that plays
a major role in the suppression of tumor cell proliferation. TNF-alpha overexpression
has been found in patients with acute and chronic inflammatory arthritis both in
disease target tissues and in the systemic circulation.64–68 Because TNF has been
implicated as one of the critical pathologic cytokines when over-expressed in the in-
flammatory cascade, much work has been done to inhibit or antagonize TNF. Three
drugs inhibiting TNF, Etanercept (fusion protein), Adalimumab (D2E7) (human
monoclonal antibody) and Infliximab, (chimeric monoclonal antibody) have been de-
veloped and are currently FDA approved for various types of inflammatory diseases.
Although the role of pro-inflammatory cytokines such as TNF-α in the pathogenesis
of inflammatory diseases has been shown to be significant, there is a large inter-and
intra-individual variability in the level of cytokine expression.69,70 Obtaining accurate
information on cytokine expression in joints affected by inflammatory arthritis could
be helpful in optimizing and/or evaluating the efficacy of biological drugs. Currently,
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there is no noninvasive nonionizing molecular imaging modality with both high sen-
sitivity and good spatial resolution which can enable drug delivery monitoring and
therapeutic evaluation of inflammatory joint diseases.
The objective of this research is to realize molecular imaging and drug delivery
monitoring for inflammatory joint diseases with both excellent sensitivity and high
resolution by using novel PAI technology aided by the newly developed gold nanorod
contrast agent. Gold nanoscale, and more specifically nanorod conjugates, also may
have pharmaceutical benefits in light of the history of gold applications in various
types of inflammatory arthritis. As an essential step toward our ultimate goal, in this
study the bioconjugation between GNRs and Etanercept, an FDA-approved anti-
rheumatic drug that inhibits TNF-α, was verified through ELISA experiment. The
feasibility of PAI in imaging the distribution of the gold-nanorod-conjugated drug




A PAI prototype system for joint imaging was employed in this study, as shown
in Fig. 3.1.71
The wavelength of the laser light was tuned by the OPO to 680 nm, which is close
to the absorption peak of the employed GNRs and enabled good penetration depth
in biological tissues. For 2D imaging of a joint cross section, a circular scan was
conducted with the sample rotated axially while keeping the transducer and the laser
beam static. In order to cover a 2π angle of view, the circular scan was conducted
at 240 positions with a constant interval of 1.5◦. To reconstruct a photoacoustic
image presenting the heterogeneous optical absorption in the sample, a modified back-
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Figure 3.1: (A) Schematic of the PAI setup. (B) Scanning geometry on rat tail joints
in situ
projection algorithm was employed.7,26,72,73 The back-projection was performed in
the time domain, where the positions of the absorbing objects were determined by
the time-of-flight and the acoustic velocities in the sample. To reconstruct an image,
the measured signals, after a derivative, were back-projected into the image space and
then integrated over all receiving angles. The transducer (XMS-310, Panametrics)
employed in this study had a central frequency of 10 MHz and a full width at half-
maximum (FWHM) amplitude bandwidth of ∼100%.
3.2.2 GNRs and anti-TNF-α conjugation
One of the key techniques involved in this study is the preparation of bioconjugates
of GNRs with Etanercept molecules, complex anti-TNF-α antibodies. GNRs with
average aspect ratio of 3 (45 nm by 15 nm) and an absorption peak at 660 nm were
synthesized.30,57,58 Both oxygenated- and deoxygenated-hemoglobin, the two major
intrinsic absorbing substances in articular tissues, have comparatively low optical
absorption in the spectra region between 650 and 720 nm.74 By setting the absorption
peak of GNRs in this region, we will have better imaging depth and enhanced signal-
to-noise ratio in imaging the GNR-based contrast agent in the joint.
The synthesized GNRs have a bilayer of surfactant hexadecyltrimethylammonium
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bromide (CTAB) on their surface which acts as a stabilizer to prevent aggregation.
The GNRs have a net positive charge on their surface because of the stabilizer. Excess
CTAB in the solution is removed by centrifugation at 5900 rpm for 60 min. The GNRs
form a pellet at the bottom of the tube which was redispersed in deionized water.
The GNRs are finally dispersed in deionized water to achieve a molar concentration
of 0.01 M of gold in the solution. A layer of polyacrylic acid (PAA) is adsorbed onto
the surface of GNRs by adding 1.5 mL of 1 mg/mL PAA solution to 1 mL of the
gold nanorod solution.30 The mixture is stirred for 3 h followed by two cycles of
centrifugation and redispersion to remove excess PAA in the solution. The layer of
PAA provides the -COOH functional group required for the conjugation. The PAA-
coated GNRs are dispersed in 1 mL of PBS 6.0 buffer solution followed by the addition
of 100 µl of 0.2 M EDC (N-ethyl-N-(3-dimethylaminopropyl) carbodiimide) and 100
µl of 0.2 M NHS (N-hydroxy-succinimide).60–62,75,76 After waiting for 20 min, the
reaction mixture is added to 12.5 mg of Etanercept. The EDC/NHS mixture forms
an active ester intermediate with the GNRs which undergoes an amidation reaction
with the -NH2 group in the anti-TNF-α to yield the conjugate. The reaction mixture
is stored in a refrigerator at 4  overnight following centrifugation and redispersion
in the buffer to remove the unconjugated drug.
3.2.3 Sensitivity of PAI in detecting GNRs
Before the experiments on animals, we validated the maximum sensitivity of the
current PAI system in detecting GNRs through a study on a well-controlled phantom.
The GNRs were diluted with PBS buffer to a concentration of 108 nanorods/mL, that
is of the order of 1 pM. Then the nanorod solution was injected into glass tubing with
a 1.7 mm inner diameter which was put into the PAI system working at 680 nm. The
orientation of the glass tubing was orthogonal to the ultrasound detection beam and
the distance between the tubing and the transducer surface was 5 cm. The recorded
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signal intensity as a function of time is shown in Fig. 3.2. The gold nanorod solution
was injected from 400 s; before that time, the signal was from the background (i.e.
saline). With concentration of the order of 1 pM, GNRs can be detected by the PAI
system with a signal-to-noise ratio (SNR) up to 4.
Figure 3.2: Photoacoustic signal from the gold nanorod solution with a concentration
of 1 pM
3.2.4 ELISA experiment
An ELISA experiment was performed to prove the bioconjugation and to show
that the anti-TNF-α drug conjugated with GNRs was still biologically active. Hu-
man TNF-α screening set purchased from ENDOGEN
®
was used. All experiments
were performed in sterile conditions. The wells of the ELISA plate were coated with
coating antibody and incubated overnight at room temperature. The coating anti-
body solution was aspirated next morning and 300 µl of blocking buffer (4% BSA,
5% sucrose in D-PBS buffer) was added to all the wells and incubated for 1 h. The
blocking buffer was then aspirated and the plate was allowed to dry for 1 h. Using
reagent diluents (4% BSA in D-PBS buffer) lyophilized human TNF-α was reconsti-
tuted to a concentration of 2000 pg/mL and coated onto the wells. After incubation
for 1 h the wells were washed with wash buffer three times. The conjugated GNRs
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were incubated for 1 h followed by three washes. Control experiments with unconju-
gated GNRs were also performed in parallel. To check for reproducibility/deviations
in data, GNRs conjugated with Etanercept were placed in 18 wells, while the con-
trol (unconjugated GNRs) was placed in 10 wells. After three washes, absorbance of
each well in the ELISA plate was measured using a microplate reader (ν max kinetic
microplate reader, Molecular Devices).
3.2.5 Rat model
Rheumatic disease rat models, including those with inflammatory arthritis, have
been researched extensively and provide the opportunity to evaluate pathologic pro-
gression much more quickly than in humans.77–79 Rat tail joints, due to their ap-
proximate size and morphological similarity to human finger and toe joints, provide
reasonable examples for research purposes. In total, four adult Sprague Dawley rats
(∼ 300 g, Charles River Laboratory) were included in this study. Whole tails were
harvested from the rat bodies within 1 min after the rats were sacrificed. An elec-
trocautery device (SurgiStat, Valleylab) was then used to clot blood and seal vessels.
The rat tail was placed in the PAI system along the Z axis (see Fig. 3.1). The
first proximal segment of the rat tail was fixed on a rotational stage that, driven
by a stepper motor, could rotate the tail around its axis. The imaged joint was
about 2.5 cm from the rat trunk, where the diameter of the tail was ∼8 mm and the
length of a segment was ∼10 mm. Administration of Etanercept-conjugated GNRs
was conducted intraarticularly through a needle. To obtain histological photographs,
rat tails were saved in 10% buffered formalin for 3 days. Tails were then decalcified
with formic acid for 4-7 days and monitored with a Faxitron MX-20 X-ray system.
Once specimen decalcification was completed they were dehydrated with graded al-
cohol (Hypercenter XP by Shandon), embedded in paraffin (Paraplast Plus), cut into
blocks and sectioned to 7 µm thickness with a Reichert-Jung 20/30 metal knife (paraf-
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fin microtome). Hematoxylin and eosin staining of specimen sections on glass slides
was conducted. Finally, the histological photographs of specimen sections were taken
with a 10× magnification
3.3 Results
3.3.1 Outcomes of ELISA experiment
The absorbance of all the wells, including 18 wells where GNRs conjugated with
Etanercept were incubated and 10 wells were unconjugated GNRs were incubated,
are shown in Table 3.1. The average absorbance of gold nanorod-Etanercept wells
is 0.132±0.028, while the average absorbance for control wells is 0.040±0.016. The
absorbance by the conjugated GNRs is more than three times higher compared to the
control experiment. This result clearly indicates that the GNRs are conjugated with
Etanercept and the nanorod-Etanercept conjugate is still active with a high affinity
for TNF-α.
AuNR-Etanercept Control
1 2 3 4 5
A 0.149 0.106 0.093 0.048 0.038
B 0.16 0.118 0.086 0.026 0.024
C 0.164 0.111 0.072 0.033 0.059
D 0.138 0.16 0.153 0.022 0.053
E 0.149 0.16 0.138 0.068 0.032
F 0.13 0.148 0.144
Table 3.1: Absorbance of each well in the ELISA plate
After making the measurements with the microplate reader, the wells in the ELISA
plate were also put in the PAI system working at 680 nm wavelength to examine the
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sensitivity and accuracy of PAI in quantifying the optical absorption from the conju-
gated GNRs. Considering the possible inhomogeneity of the gold nanorod distribution
in each well, PAI measurement of each well was conducted four times each at different
locations. The average photoacoustic signal intensity and the standard error for each
well is shown in Fig. 3.3, where photoacoustic (PA) measurements present a good
linear relationship with the readouts from UV/vis (p<.0001).
Figure 3.3: Photoacoustic measurements of the optical absorbance of ELISA wells in
comparison with the UV/Vis readouts
The small discrepancy between PAI results and UV/vis readouts may come from
the fluctuation of laser energy and the inhomogeneous distribution of GNRs in each
well. Besides the good correlation between PAI and UV/vis outcomes, we can also see
clearly the difference between the PAI results from the GNRs-Etanercept conjugates
and those from the control.
3.3.2 Imaging on rat tail joints
2D photoacoustic cross-sectional imaging of rat joints in situ was conducted with
laser light at 680 nm. Fig. 3.4 shows an example A-line of the photoacoustic signal
from the imaged rat tail joint. The signal from the GNRs diffused in intraarticular
connective tissue can be recognized with an excellent SNR of up to 17, where the
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amplitude of the noise was measured from the background before the arrival of the
signal from the tissue.
Figure 3.4: A-line photoacoustic signal from the imaged rat tail joint with the contrast
enhanced by the GNRs
The image in Fig. 3.5(A) was taken before the administration of Etanercept-
conjugated GNRs, while the images in Fig. 3.5(B)&(C) were taken after the first
and the second administrations of the contrast agent. The injections were conducted
intra-articularly through a needle via the direction indicated by the arrows in the
images. For both the first and the second injections, 0.025 mL agent with a gold
nanorod concentration of 109 nanorods/mL (i.e. 10 pM) was introduced. The total
number of GNRs introduced into the regional joint space for each injection was of
the order of 107. All the other experimental parameters for the images in figures
3.5(A)-(C) were the same, except that the specimen might be moved slightly during
the administration of the contrast agent.
With the optical contrast enhanced by the GNRs, the contour of the intra-articular
connective tissue is presented much more clearly in the images in Fig. 3.5(B)&(C) in
comparison with the image in Fig. 3.5(A), which is based on the intrinsic tissue con-
trast. The hexagon shaped contour of the intra-articular connective tissue has been
verified by the histological photograph of a similar cross section in a rat tail joint.
The findings in Fig. 3.5(B)&(C) are also consistent: with more GNRs injected and
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Figure 3.5: 2D cross-sectional PAI of a rat tail joint. (A) Image based on intrinsic
contrast, which was taken before the administration of the contrast agent. Images
taken after (B) the first and (C) the second administration of Etanercept-conjugated
GNRs. For each administration, 0.025 mL agent with a 10 pM concentration was
injected intra-articularly through the arrows in the images. (D) Histological photo-
graph of a similar cross section in a rat tail joint showing the morphological features
including intra-articular tissue, vessels and muscle
diffused in the intra-articular connective tissue more areas of tissue were ‘lightened’.
This study has proved the capability of photoacoustic technology in tracing and quan-
tifying goldnanorod-based contrast agents in biological tissues. With our current PAI
system, the spatially distributed gold nanorod contrast agent with a concentration
down to 10 pM in biological tissues can be imaged with very good signal-to-noise
ratio and high spatial resolution.
3.4 Conclusions
In conclusion, this study demonstrates the feasibility of a gold nanorod contrast
agent to enhance joint imaging utilizing novel PAI technology. PAI, by combining
the merits of both light and ultrasound, overcomes some limitations of conventional
optical and ultrasound imaging modalities. With our current system, PAI presents a
maximum sensitivity of the order of 10 pM in imaging GNRs in conjugation with an
anti-TNF-α drug. This sensitivity is parallel to conventional optical imaging in de-
tection and quantifying a gold nanoparticle contrast agent.80–82 Unlike conventional
24
optical technologies, the spatial resolution of PAI is excellent (of the order of 250 µm,
and may be improved further by adjusting the detection bandwidth) in visualizing
subsurface joint tissues and the spatially distributed contrast agent. The good reso-
lution of PAI especially benefits the imaging of drug delivery and treatment effects in
peripheral joints which are among the earliest to be affected by rheumatoid arthritis
and are widely accepted to be the best markers of overall joint damage.
With further development of PAI technology, highly sensitive imaging of drug
delivery in combination with high resolution high contrast anatomical imaging may
be achieved through a single exam without the need for image fusion. PAI may enable
investigators to follow the drug and/or the delivery vehicle on its journey through
the body to ascertain whether successful drug uptake is occurring in the desired
organ, such as arthritic joint tissues. Moreover, the good sensitivity of PAI to joint
tissue morphological changes and functional hemodynamic changes may also make
this technology promising in the evaluation of treatment efficacy. Other advantages
of PAI which will also benefit laboratory research and future clinical practice involving
molecular imaging include being nonionizing and relatively cheap when compared to
other modalities such as magnetic resonance imaging and nuclear imaging.
In future studies, PAI of drug delivery monitoring will be conducted on arthritic
animal models in vivo with systemic administration of drug-conjugated GNRs. Effi-
cacy and toxicity of such applications will also be studied. Moreover, a multi-channel
ultrasound unit with a well-designed ultrasonic array transducer will be employed
to replace the single-element transducer for image acquisition. With this more ad-
vanced imaging system, the sensitivity and resolution as well as the speed of PAI for
molecular imaging may be improved significantly.
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CHAPTER IV
Dual Mode Imaging with Radiolabeled Gold
Nanorods
4.1 Introduction
Nanoparticle bioconjugates represent contrast agents for a variety of imaging and
treatment techniques which take advantage of unique light-absorption, emissive, or
magnetic properties of quantum confined solids.83–87 One of them, photoacoustic
imaging (PAI), is a non-ionizing, non-invasive biomedical imaging modality which
combines the merits of both light and ultrasound.8,9, 16,34 In PAI, a short pulsed laser
is used to illuminate the tissue and generate photoacoustic waves due to thermoelastic
expansion. The laser generated signal is then measured by broadband ultrasound
transducer(s) to reconstruct the image in the tissue sample. PAI is highly sensitive
to the optical absorption contrast in the tissue; while its spatial resolution is limited
mainly by ultrasound detection rather than by the overwhelming light scattering as
in diffuse optical imaging.
Despite the variety and relative effectiveness of PAI contrast agents available, there
is an inherent disadvantage in PAI measurements due to the strong attenuation of
light in biological tissues as well as the high background signal as a result of intrinsic
tissue optical absorption. PAI presents local spatial resolution on the sub-millimeter
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level however the penetration depth limits its ability to make measurements with
satisfactory signal-to-noise ratio deep inside the tissue. In fact, the same problem is
present for all nanoparticle contrast agents based on optical emission, which became
increasingly popular recently.88,89 This inherent problem of light emission can be
overcome indirectly by merging it with another imaging modality which can provide
high signal-to-noise ratio even deep inside the tissue and assist to validate the findings
of the other technique.
In this study, we have successfully fabricated a targeted optical and nuclear dual-
modality agent by radiolabeling GNRs with [125I] to monitor anti-TNF-α drug de-
livery. The high contrast-to-noise ratio and good quantification of nuclear imaging
provide a gold standard and assist to validate PAI findings; while PAI helps overcome
the spatial resolution limitations of nuclear imaging and demonstrates regional infor-
mation with improved accuracy. As demonstrated in our initial experiments on rat
joints in situ, the distribution of radiolabeled GNRs in articular tissue can be pre-
sented by both PAI and Single-Photon Emission Computed Tomography (SPECT).
Moreover, by covalent binding of radioisotopes on the surface of targeted gold NPs,
nuclear imaging such as PET and SPECT can for the first time image the concen-
tration and distribution of gold NP based agents in vivo, which could contribute
considerably to understanding of the toxicity and pharmacokinetics of any novel gold
nanocolloids in the future.
4.2 Experimental Section
4.2.1 PAI setup
The photoacoustic experimental setup is given in Fig. 3.1. Laser pulses from an
optical parametric oscillator (OPO) (Vibrant B, Opotek) pumped by an Nd:YAG
laser (Brilliant B, Bigsky) were used to illuminate the sample, either a ELISA well
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plate as in Fig. 3.1(A) or joints in a rat tail as in Fig. 3.1(B). The laser pulse
repetition rate was 10 Hz and each pulse had a width of 5.5 ns. The laser wavelength
was tuned to 760 nm, the absorption peak of the GNRs. An optical diffuser was used
to expand the laser beam to cover a well or a joint completely. The energy density of
the laser pulses incident at the sample was adjusted to less than 10 mJ/cm2, within
the ANSI safety limit. A part of the laser beam was reflected off by a glass plate and
was measured by using a photodiode in order to take into account the incident light
energy and the laser fluctuation. Neutral density filters were placed in the beam path
to limit the maximum amount of light enter into the photodiode. For the experiment
on ELISA well plate, an unfocused ultrasonic transducer (XMS-310, Panametrics)
with a central frequency of 10 MHz, -6 dB bandwidth of 133% and a diameter of
2 mm was used to collect the photoacoustic (PA) signals from the illuminated well.
Part of the well and the transducer were immersed in water for acoustic coupling.
For the imaging of rat tail joints, a focused transducer (V312, Panametrics) with a
central frequency of 10 MHz, -6 dB bandwidth of 130%, a diameter of 0.25 inch, and
a focal length of 0.75 inch was used to conduct a raster scan along the length of the
tail. PA signals received by the transducer were amplified (PR5072, Panametrics)
and sent into one channel of a digital oscilloscope (TDS 540B, Tektronics) which was
triggered by the laser firing. The signal from the photodiode was sent into another
channel of the oscilloscope. The signals received by the oscilloscope were digitized,
collected and stored in a computer for processing and analysis. The amplitude of the
PA signal was divided by the photodiode signal amplitude to get the photoacoustic
response.
4.2.2 Gamma imaging setup
Radionuclide imaging was performed using the Gamma Imager (Biospace Lab,
Paris). The planar imaging for ELISA experiments was performed with Gamma
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Imager detection area facing upwards and a ELISA well plate was placed directly
on the parallel hole collimator 1.3/0.2/20 (hole diameter/septum thickness/height
in mm). 15 minute duration image was acquired using energy window 15-70 KeV,
and the image was then displayed and quantified using Gamma Vision+ software
(Version 3.0). Radioactivity was determined by drawing regions of interest (ROI)
and calculated based on standard curve, which is generated by scanning a series of
standards with known radioactivities.
4.2.3 MicroSPECT/CT
SPECT/Computed Tomography (CT) was performed using a pair of collimators
(1.3/0.2/35) stand up to orient the detection area towards the animal (rat tail). The
rat tail was fixed on a holder and aligned parallel to the face of detector. After
36 minutes CT scan, a 30 minute gamma imaging was acquired and 2D image was
reconstructed using Gamma Acquisition software. The reconstructed fusion image of
SPECT/CT could be displayed and quantified using Amira software (Version 3.1).
4.2.4 Synthesis of the GNRs
GNRs are synthesized by a method modified from literature.57,90–92 Briefly, a
seed solution is prepared by reducing Gold (III) Chloride (25 µL, 0.05 M) in Hex-
adecyltrimethyl ammonium bromide (4.7 ml, 0.1 M) by addition of freshly prepared
Sodium Borohydride (0.3 ml, 0.01 M) under vigorous stirring. An aliquot of seed
solution (0.24 mL), is added to the growth solution containing Hexadecyltrimethyl
ammonium bromide (100 mL, 0.1 M), Gold (III) Chloride (1.0 ml, 0.05 M), Hy-
drochloric acid (2 mL, 1 M), Ascorbic acid (0.8mL, 0.1 M)and Silver Nitrate (1.2
mL, 0.01 M). The glass beaker is placed in a water bath maintained at 27  for
three hours to complete the synthesis. 50 mL aliquots of the synthesized rods are
centrifuged at 10000 rpm for 1 h to obtain pellet of GNRs at the bottom of the tube.
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Supernatant is decanted and the pellet is redispersed into 5 mL of deionized water
to get a concentration of 1013 rods/mL. GNRs with average aspect ratio of 4 are
obtained with transverse plasmon peak at 525 nm and longitudinal plasmon peak at
around 800 nm. The position of the longitudinal plasmon peak can be fine tuned
fairly easily within 600-900 nm range by varying the content of silver nitrate during
synthesis.
4.2.5 Gold nanorods and anti-TNF-α conjugation
Bioconjugation was performed by a slightly modified method previously published
by our group.36–38,60–62,93 A layer of polyacrylic acid (PAA) is adsorbed onto the sur-
face of GNRs by adding 1.0 mL of 1 mg/mL PAA solution to 1 mL of the prepared
GNRs solution. The mixture is stirred for 3 hours followed by centrifugation to
remove excess PAA in the solution. The layer of PAA provides the -COOH func-
tional group required for the conjugation. The PAA-coated GNRs are dispersed in
1 mL of deionized water followed by the addition of 100 µL of 0.2 M EDC (N-ethyl-
N-(3-dimethylaminopropyl) carbodiimide) and 100 µL of 0.2 M NHS (N-hydroxy-
succinimide). After waiting for 20 min, the reaction mixture is added to 12.5 mg
of Etanercept, an FDA approved biologic disease modifying anti-rheumatic drug
(DMARD) targeting TNF-α. The EDC/NHS mixture forms an active ester inter-
mediate with the GNRs which undergoes an amidation reaction with the -NH2 group
in the anti-TNF-α to yield the conjugate. The reaction mixture is stored in a refrig-
erator at 4  overnight following centrifugation and redispersion in deionized water
to remove the unconjugated drug.
4.2.6 Radiolabeling of GNRs with 125I
[125I] Radionuclide in 10−5 M NaOH (pH 8-11) purchased from PerkinElmer (100
mCi/mL) was diluted with deionized water. The concentration was determined upon
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radioactivity. GNRs (either blank or conjugated with drug) dispersed in fresh deion-
ized water (0.5 mL, 1013 rods/mL) was added to 0.5 mL diluted [125I] sodium iodide.
The mixture was shaken for 30 minutes at room temperature. The [125I]-iodine labeled
GNRs were then washed with deionized water by centrifugation and redispersion.
4.2.7 Outcomes of ELISA experiment
Human TNF-α screening set purchased from ENDOGEN® was used. All experi-
ments were performed in sterile conditions. The wells of the ELISA plate were coated
with coating antibody and incubated overnight at room temperature. The coating
antibody solution was aspirated next morning and 300 µL of blocking buffer (4%
BSA, 5% sucrose in D-PBS buffer) was added to all the wells and incubated for 1
hour. The blocking buffer was then aspirated and the plate was allowed to dry for 1
hour. Using reagent diluents (4% BSA in D-PBS buffer) lyophilized human TNF-α
was reconstituted to a concentration of 2000 pg/mL and 100 µL was added into the
wells. After incubation for 1 hour, the wells were washed with wash buffer three
times. 100 µL of GNRs conjugated with drug were added into each alternating well
in Row A; 100 µL GNRs conjugated with drug and radiolabeled (30 µCi) were added
into each alternating well in Row C; 100 µL radiolabeled (30 µCi) GNRs into each
alternating well in Row E; and 100 µL blank GNRs into each alternating well in Row
G. In each row, 4 alternating wells were used in order to average the results. After
incubating the samples for 1 hour, the 96 well plate was aspirated and washed with
washed buffer three times. The dried plate was analyzed with PAI setup and Gamma
imager.
4.2.8 Rat tail joint model
The GNRs concentration in original solution is 1013 rods/mL. The original so-
lution was diluted 40 times first with distilled water and then 0.2 mL of solution
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was mixed with 0.5 mL of I-125 with radioactivity of 400 µCi for 30 min using a
ROTAMIX rotates (Appropriate Technical Resources, Inc., Laurel, MD). The mix-
ture was centrifuged for 4 min at the speed of 5000 cpm in 1 mL tube. Then the
radiolabeled GNRs at the bottom of the tube were taken out and diluted again to
0.3 mL with distilled water (∼320 µCi). Therefore, in this solution (named agent
#1), the GNRs concentration was 1011 rods/mL (i.e. 2×10−10 M or 200 pM). After
the agent #1 was made, 1 mL of solution was diluted 1:1 with distilled water which
makes agent #2 with a GNRs concentration of 1×10−10 M (or 100 pM). After that,
1 mL of agent #2 was diluted further 1:1 with distilled water to get agent #3 with
a GNRs concentration of 5×10−11 M (or 50 pM). As shown in Fig. 4.3(A), 0.02 mL
of contrast agents #1, #2 and #3 were injected intra-articularly in every other joint
in the rat tail; while same amount of water (i.e. 0.02 mL each) was injected in the
other two joints as control. The estimated total amounts of GNRs injected in the
three joints were 2×109, 1×109 and 5×108, respectively. Considering that some of
the GNRs may stay in the upper medium in the tube after centrifuge, the actually
number of GNRs injected should be mildly lower. Measured with a Capintec dose
calibrator (CRC-543X, Capintec Inc., Ramsey, NJ), the total radioactivities of GNRs
injected in the three joints were 15.2 µCi, 7.4 µCi and 3.6 µCi, (roughly at a ratio of
4:2:1)
Whole tails of euthanized rats were imaged. An optical beam with size of 1 cm
in diameter and wavelength at 760 nm illuminated the imaged rat tail and generated
photoacoustic signals that were acquired with the focused V312 Panametric trans-
ducer. The distance between the transducer and the rat tail was about 19 mm which
was also the transducer focal length. Considering an f-number of 3 and, the estimated
lateral resolution was about 0.55 mm; while the estimated axial resolution was about
0.12 mm. In order to acquire a 2D image along a sagittal section of the tail, the tail
immersed in water for ultrasound coupling was positioned through a computer con-
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trolled stepper motor while the transducer and the laser beam were kept static. The
scanning step was 0.6 mm (similar to the lateral resolution) and the scanning period
was 60 mm (i.e. 100 steps). The total period for photoacoustic signal acquisition was
about 10 min when the signal at each scanning position was averaged over 50 laser
pulses to achieve better signal-to-noise ratio.
4.3 Results
4.3.1 Radiolabeling of GNRs with 125I
Figure 4.1: UV-Vis spectra of the GNRs solution before and after radiolabeling the
drug conjugated GNRs with 125I
The radiolabeling procedures are simple and reliable, with radiochemical yields
greater than 80%. GNRs were found to be stable after binding with radioactive
iodine. This agreed well with published data which claims that there is high affinity
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and strong binding of iodide ions to the surface of GNRs.94 Figure 4.1 shows the UV-
Vis absorption spectra of the GNRs conjugated with drug before and after addition
of radioactive iodine. The minor blue shift in the spectrum is due to the change in
the surrounding of the GNRs surface due to addition of iodine molecules.
4.3.2 ELISA experiment
Figure 4.2: Left: Mean ± standard deviation of photoacoustic signal intensity mea-
sured from each row of the ELISA plate. Right: γ-camera image of the ELISA plate.
Row A contains (GNRs + drug) Row C contains (GNRs + drug + 125I); Row E
contains (GNRs +125I); and Row G contains (GNRs). The photoacoustic signal and
radioactive image correspond very well
ELISA experiment has been performed to evaluate the biological activity and the
specific binding of the synthesized contrast agent carrying anti-TNF-α, which is an
important therapeutic agent against arthritis. Row C with radiolabeled conjugated
GNRs showed strong signal in both gamma imager and photoacoustic measurements
(Fig. 4.2). The control in row E had very weak photoacoustic amplitude (PA) signal
and nearly zero radioactivity because the GNRs lacked the anti-TNF-α drug on their
surface to cause specific binding on the well plate. Row A with GNRs conjugated
with drug showed similar photoacoustic signal amplitude as row C but no radioactivity
because it was not radiolabeled with 125I. Another control of row G with blank GNRs
also had very weak photoacoustic signal and nearly zero radioactivity. The finding
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from the ELISA experiment concludes that the drug conjugated with 125I labeled
GNRs retains its biological activity and forms a highly specific system. The ratio of
photoacoustic signal for specific (average PA amplitude from area under row C) to
non-specific binding (average PA amplitude from area under row E) for the targeted
radiolabeled GNRs contrast agent was 6:1. The ratio of signal intensity in the γ-
camera image for specific (average intensity from area under row C) to non-specific
binding (average intensity from area under row E) for the targeted radiolabeled GNRs
contrast agent was 6.125:1. This also shows a strong one to one correspondence in
results obtained respectively from the photoacoustic and nuclear imaging setups.
4.3.3 Imaging results on rat tail joints
After the first photoacoustic image was taken (Fig. 4.3(B)), intra-articular injec-
tions of contrast agent and water were conducted. Then the second photoacoustic
image was taken, as shown in Fig. 4.3(C). The signal enhancement can be seen in
the three joints with injected radiolabeled GNRs contrast agent; while no noticeable
change can be seen in the two joints with water injected. The maximum signal in-
tensities in the three marked areas in Fig. 4.3(C) show a ratio of 1.16:0.60:0.27 that
is close to ratio among the doses of injected contrast agent in the three joints (i.e.
4:2:1). After photoacoustic data were acquired, the rat tail was placed in our mi-
croSPECT/CT system. The 2D images of SPECT and CT are shown in Fig. 4.3(E)
and Fig. 4.3(A), respectively. As shown in Fig. 4.3(A), the acquired 2D microCT
image of the sagittal section of the rat tail shows clearly the bone structure. This
microCT image was then fused with the photoacoustic image in Fig. 4.3(C). In the
microCT and photoacoustic combined image in Fig. 4.3(D), photoacoustic image
presents the distribution of contrast agent and some soft tissue structures; while the
microCT image describes detailed bone structure in the tail. With the morphological
information presented by the microCT image, we can see clearly that the positions of
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signal enhancements in the photoacoustic image were at the intra-articular connective
tissues in the three joints containing the contrast agent.
As shown in Fig. 4.3(E), when the GNRs concentration in the target tissue was
on the order of 10 pM, the radioactivity from 125I conjugated with the GNRs was
sufficient to enable nuclear imaging with excellent signal-to-noise ratio. The counted
radioactivities in the three joints with injected contrast agent were 4939, 2702 and
1453 counts/min respectively. The ratio among them is also close to that among the
contrast agent doses in the three joints (i.e. 4:2:1). In Fig. 4.3(F), nuclear imaging
is fused with the microCT image presenting both the distribution of contrast agent
and the morphological tissue structures.
4.4 Discussion
Non-invasive monitoring of drug delivery in experimental models and in clinical
settings would undoubtedly be very helpful for both basic research and pharmacologic
management of a variety of diseases including rheumatoid arthritis. In this work, by
imaging the 125I labeled GNRs, both PAI and SPECT have successfully presented the
distribution of GNRs conjugated anti-rheumatic agent in intra-articular connective
tissues. In comparison with PAI, nuclear imaging should be superior in whole body
imaging and in quantification due to good tissue penetration of γ-rays. However, the
target specificity of nuclear imaging can be compromised due to its limited spatial
resolution. In contrast, PAI presents spatial resolution on the sub-millimeter level (or
even micrometer level by performing photoacoustic microscopy) and, hence can be
superior in localizing contrast target taken up by regional target tissues.95,96 The mea-
surements from PAI, however, is difficult to be quantified, mainly due to the strong
attenuation of light in biological tissues as well as the high background signal as a re-
sult of intrinsic tissue optical absorption. For the same reasons, we expect that PAI is
also inferior in contrast-to-noise ratio compared to nuclear imaging in detecting radi-
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Figure 4.3: In situ imaging of radiolabeled GNRs contrast agent in rat tail joints. (A)
MicroCT image of a sagittal section of a rat tail with joint sections clearly presented.
As marked in the image, intra-articular injection of contrast agent or water as control
was conducted in each joint. Photoacoustic image of the sagittal section in the rat
tail (B) before and (C) after intra-articular injection of contrast agent. The signal
enhancements in the three joints with injected contrast agent are marked with dashed
ellipses. (D) The photoacoustic image in (C) fused with the microCT image in (A).
(E) SPECT image of the sagittal section in the rat tail presenting the radioactivities
in the three joints with the injected contrast agent. (F) The SPECT image in (E)
fused with the microCT image in (A)
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olabeled optical contrast agents. By fabricating the radiolabeled gold NPs conjugated
with drug and performing the dual-modality imaging as described in this work, one
may combine the advantage of high contrast-to-noise ratio and good quantification
of nuclear imaging with the advantage of high spatial resolution of PAI. Moreover, as
an emerging optical imaging modality, adaptation of PAI to functional and molecular
imaging is still in the early stages and needs further development. With unparalleled
high sensitivity, nuclear imaging especially when combined with microCT could pro-
vide a very powerful tool and gold standards to validate the imaging findings from
novel PAI technique. On the other hand, while GNRs have been used extensively as
optical contrast agents, the radiolabeling and use of NPs as SPECT agents have only
recently been explored. NPs are well-suited to the design of SPECT probes, because
their relatively large surface area (as compared with traditional small-molecules) can
be labeled to a high specific activity. This allows for increased sensitivity of detection
and increased payload of targeting ligands and therapeutic isotopes. Using the setups
described above, we could image conjugated GNRs with a radioactive label of 5 µCi,
down to a concentration of 10 pM in articular tissues. This provides evidences that
the technologies of nuclear imaging and optical imaging are directly compatible and
complementary.
Furthermore, we feel it is less likely that payloads including ligands and isotopes
will significantly alter the natural progression of NPs through the body with exception
to designed targeting. Obviously pharmacokinetic testing including in vivo evaluation
of this contrast agent is needed to characterize how the agent in comparison to con-
trol and in pathologic settings such as inflammatory arthritis is treated by physiologic
systems. Should the agent, due to its architecture with anti-TNF properties, localize
to inflamed joints in the setting of inflammatory arthritis, in addition to monitoring
of drug delivery it could be used to characterize quantitatively the degree of inflam-
mation within each inflamed joint. This may be very helpful particularly in animal
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and human studies. Limitations of use of this contrast agent in human studies include
the amount of ionization subjected to patients and as already mentioned potential
toxicities of NPs.
Radioactive iodine-labeled compounds have been used for decades in oncology,
thyroid disorder, renal function, and inflammations. By providing functional infor-
mation, nuclear imaging have shown advantages in identifying the present of abnor-
mality where complex anatomy renders anatomic imaging (CT) less accurate. In ad-
dition, functional imaging is always necessary for pharmacokinetic study of new drugs.
With the increasing proliferation of hybrid SPECT/CT recently, simultaneous acqui-
sition of anatomic and functional information without alteration in patient position
overcomes many of shortcomings and results in accurate localization and metabolic
characterization of pathophysiological process. Introducing new radiopharmaceuti-
cals and reintroducing older ones in the context of multimodality have considerably
expanded. The potential benefits of combining SPECT/CT with PAI are great.
Radioactive gold nanoparticles have typically been synthesized in the past by
bombarding neutron flux on Au-197 (100% isotopic abundance) to transmute into Au-
198 by neutron capture, emitting prompt gamma.97–100 The method of radiolabeling
presented in this work is much more simpler, green and requires no sophisticated
equipment. Au-198 and Au-199 with strong bate-emitting provide destructive power
to kill cancer cell as therapeutic agents. However, there will be a large unnecessary
radiation dose to the patient if used as imaging agents. I-125 with pure gamma-
emitting apparently is more suitable for imaging utilization. In addition, radioactive
iodine is also readily available as I-123 (gamma-emitter) for SPECT, I-124 (positron
emitter) for PET, and I-131 (bate-emitter) for therapy. There is a great potential to
achieve multiple applications with a single successful compound.
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4.5 Conclusions
With intrinsic advantages including small sizes, ease of preparation and bioconju-
gation, unique optical properties, as well as good biocompatibility, gold NPs including
GNRs have been explored for potentially wide application in drug delivery, cellular
imaging, and biomedical diagnostics and therapeutics (theranostics). It was shown
through the ELISA experiment in this study that the anti-TNF drug molecules keep
their bioactivity after conjugation to 125I radiolabeled GNRs and that the conjugated
system is highly specific in binding with TNF molecules. Although this work was
related to imaging, delivery and therapeutic action of anti-TNF-α, this technique of
combining radiolabel functionality and other advantages of gold NPs is quite simple
and stable and can easily be extended to targeted imaging of other disorders including
cancer. By introducing the radiolabeled gold NPs, nuclear imaging could contribute
to the understanding of how gold NPs interact with biological systems within the
context of physiologically authentic environments, and could accelerate the clinical
applications of these agents by helping to validate and optimize their diagnostic sensi-
tivity, cellular uptake, toxicity, and molecular response. We expect that radiolabeled
gold NPs could also become an efficient therapy agent with the combination of the
power of radiation therapy and photothermal therapy. Further work is needed to
produce more efficient imaging platforms compatible with animal and human use to
study the pharmacokinetics and pharmacodynamics of this contrast agent.
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CHAPTER V
In Vivo Biodistribution of 125I-Labeled Gold
Nanorods using γ-Imaging
5.1 Introduction
Nanoparticles, due to their small sizes and associated unique properties, have
been widely used in drug delivery,101–103 cellular imaging,104–106 and biomedical di-
agnostics and therapeutics.107–110 Plasmonic gold nanostructures possess intriguing
physical and chemical properties which are of interest to both fundamental science
and biomedical application.111 Among the most fascinating and useful are optical
properties as well as related photothermal properties.112 These optical properties de-
pend on nanoparticle size and shape.113,114 One can manipulate the shape of gold
nanostructures to control their electronic and associated optical properties for dif-
ferent applications.115,116 Their remarkable capacity to absorb and scatter light at
visible and near-infrared (NIR) regions is essential for optical imaging.117 In addi-
tion, gold nanoparticles can convert optical energy into heat via nonradiative electron
relaxation dynamics which endows them with intense photothermal properties.118–121
Such localized heating effects can be directed toward the eradication of diseased tissue,
providing a noninvasive alternative to surgery.122 Current nanotechnology research
suggests that gold nanoparticles form a novel class of optically active dual imaging-
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therapy agents.123–125
In particular, gold nanorods (GNRs) have attracted much interest because of their
small sizes, ease of preparation and bioconjugation, strong absorbing and scattering
properties, as well as their well-known biocompatibility.111,117,126 GNRs with well-
defined shapes and sizes are readily synthesized by seeded growth methods, and their
longitudinal plasmon resonances (LPRs) can be finely tuned as a function of aspect
ratio.37,111,126 GNRs support a larger absorption cross-section at NIR frequencies per
unit volume than most other nanostructures and have narrower line widths due to
reduced radiative damping effects with consequently higher optothermal conversion
efficiencies.117,118,127 The LPRs can also support nonlinear optical effects, such as
plasmon-enhanced two-photon luminescence (TPL).117,128 The LPRs are also sensitive
to the polarization of the incident excitation; by slightly adjusting the wavelength of
a continuous-wave (cw) polarized laser, individual GNRs can be aligned for several
minutes in an optical trap.129 These properties give rise to many exciting possibilities
to deploy GNRs for biological imaging and photothermal therapy.117 Furthermore,
the surface chemistry of GNRs allows multiple functionalizations. Capping molecules,
such as cetyltrimethylammonium bromide (CTAB), can be replaced or conjugated
with many functional groups.130,131 Target specificity of GNRs can be imparted by
tagging with certain biovectors, such as monoclonal antibodies,132 receptor-specific
peptides111 and other compounds,133 which can navigate them to desired organs or
sites. Recent studies have successfully demonstrated that GNRs with strong near-
IR absorption can be conjugated to molecules to facilitate delivery to the tumor
for subsequent efficient cancer cell diagnostics and selective photothermal therapy
simultaneously.111,132
To advance GNRs toward realistic clinical applications and to optimize their diag-
nostic sensitivity, payload, or therapeutic efficiency, it is becoming urgent to under-
stand how they interact with biological systems and their biodistribution after admin-
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istration via injection. Various in vitro studies have provided fundamental informa-
tion as to how nanoparticle size and surface chemistry greatly impact their interaction
with plasma proteins, cellular uptake, toxicity, and molecular response. However, the
in vivo environment is far more complex than in vitro model systems.132,134 For in-
stance, blood contains a variety of ions, as well as proteins, lipids, hydrocarbons, and
other components that may affect nanoparticle stability, functionality, and target-
ing.132 Studying the stability and functionality of injected GNRs within the in vivo
environment is technically challenging.
So far only very few studies have investigated the in vivo behavior of engineered
nanostructures. Although multiple studies with polymer colloids had been per-
formed,135–137 only very limited biodistribution data are available specifically for gold
colloids. A relatively recent paper indicates that gold nanorods 65 nm in length and
11 nm in diameter were found to accumulate primarily in liver, kidney, and spleen,
which is consistent with macrophage capture.131 Without surface coating, they were
removed by the reticuloendothelial (RES) system from the circulation within 30 min,
while after coating with PEG this time was extended to 72 hours. At the same time, a
different recent report give data that are difficult to correlate with those cited above.
For gold nanoparticles (NPs) 1.9 nm in diameter, which were injected into mice, reten-
tion in liver and spleen was low and circulation lifetime was several days.138 The great
difference in observations and controversies in the interpretation of the data is very
difficult to explain and requires extensive investigation. The difficulties with evalua-
tion of biodistribution, blood clearance and other key pharmacokinetic parameters of
GNR and other NPs is, in large part, related to the lack of a convenient monitoring
technique for their distribution within the body. Traditionally it was carried out by
radioactive labels, but this technology is grossly underdeveloped for nanoparticles.
This study is the initial investigation of the in vivo behavior of [125I]-iodine la-
beled gold nanorods, which represent nanoparticles with dual functionalities: plas-
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monic and radioactive labels. The stability and metabolism pattern of radiolabeled
GNRs in normal rats were successfully examined using γ-scintigraphy. Longitudinal
biodistribution studies have been performed repeatedly in the same animal for up to 6
days, therefore decreasing sources of inter-individual variation while being efficient in
terms of animal cost and ethical practice. Radiolabeling of GNRs allows systematic
study of gold nanoparticles within in vitro and in vivo microenvironments, provid-
ing a highly efficient methodology for bioevaluation of different kinds of GNRs and
their bioconjugates. The novel protocol reported here could be extensively useful for
guidance of the design and the development of new target-specific gold nanoparticles.
5.2 Experimental section
5.2.1 Synthesis of PEGylated GNRs
GNRs of average aspect ratio 4, capped with hexadecyltrimethyl ammonium bro-
mide were synthesized using the seed-mediated growth methods reported in the litera-
tures.90,91 After synthesis gold nanorods were centrifuged and redispersed in deionized
water to a final concentration of 1012 rods/mL. Polyethylene glycol thiol molecules
were dispersed in deionized water (1 mL, 50 mg/mL) and mixed with GNRs (1 mL,
1012 rods/mL). The mixture was allowed to react overnight, followed by centrifugation
and redispersion of rods to a final concentration of 1012 rods/mL. The zeta potential
of bare gold nanorods is +40 mV and after PEGylation is reduced to +8 mV (5000
mol. wt.) and +10 mV (20,000 mol. wt.)
5.2.2 Radiolabeling of GNRs
In general, 0.1 mL of GNRs with concentration of 1012 rods/mL in deionized
water was placed into a polypropylene microcentrifuge tubes (1.5 mL) and 0.5 mL
of diluted [125I]NaI was added, roughly 300 µCi of radioactivity. The vial was ro-
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tated on a ROTAMIX rotates (Appropriate Technical Resources, Inc. Laurel, MD).
The mixture was then centrifuged at 5000 rpm using a Beckman Microfuge II. The
supernatant was decanted and pellets were re-dispersed in 0.1 mL of fresh sterile fil-
tered deionized water. Various reaction times of 2, 10, 20, and 30 minutes have been
tested, as well as various centrifugation periods of 5, 10, 15 and 30 minutes. The
optical absorption spectra of diluted GNRs in saline solution were measured before
and after radiolabeling by using a spectrophotometer (Perkin Elmer, MA, USA) with
the sample contained in a 1 cm pathlength plastic cuvette.
5.2.3 Stability of GNRs in blood circulation
The experiments were performed according to the guidelines of the University
Committee on Use and Care of Animals, University of Michigan. Male Sprague-
Dawley rats (∼250g) were purchased from Charles River Laboratories (Wilmington,
MA). The rats were anesthetized using an isoflurane anesthesia machine. Two I.V.
catheters were placed into lateral tail veins separately, one for injection of the 125I-
GNRs dose and another for extraction of blood samples. The catheters were rinsed
with 0.2 mL of saline after injection and every extraction. 125I-labeled gold nanorods
prepared as mentioned above were injected into rats through a tail vein, about 120
µCi in 0.1 mL of water for each animal. 3 rats were used for each kind of GNRs. Blood
samples (0.1 mL) were collected from another tail vein at set times, from 1 minute
to 4 hour post-injection. Radioactivity in each blood sample was counted using a
γ-counter (MINAXI Auto-gamma 5000 Series, Packard Instrument Co., Grove, IL).
5.2.4 Long-term biodistribution using γ-imaging
The same group of animals used for blood assays were imaged at set times between
blood sampling. After the measurements in day 1, the animals were re-anesthetized
and scanned once each day from day 2 to day 6 before they were sacrificed. Each
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image was acquired in 5-minute on an anesthetized rat placed in anterior position
over the parallel-hole collimator 1.8/0.2/20 (Hole diameter/septum thickness/height
in mm) of a Gamma Imager (Biospace Lab, Paris). Radioactivity was then quantified
by drawing regions of interest (ROI) using Gamma Vision+ software (Version 3.0).
For each animal, ROIs were drawn around the liver/spleen and heart/lung and were
saved to be re-used systematically for longitudinal follow-up.
5.3 Results and Discussion
5.3.1 Preparation of 125I-labeled GNRs
GNRs of average aspect ratio 4, either bare or PEGylated, were radiolabeled by
simply mixing with [125I] sodium iodide in deionized water at room temperature. The
reaction takes place very rapidly and completely, with radiochemical yields greater
than 90% by radioactivity count. There were no significant differences observed when
the mixtures of [125I] sodium iodide and GNRs were mixed for 2, 10, 20, or 30 minutes
prior to centrifugation. This agrees well with the prior reports of high affinity and
strong binding of iodide ions to the surface of gold nanorods.94,126,139 It has previously
been reported that iodide ions may affect the shape and size of GNRs.139 In our case,
the concentration of iodide is extremely low and has no significant impact on the
optical property of GNRs. Fig. 5.1 shows the absorption spectra of GNRs measured
before and after radiolabeling. The longitudinal plasmon peaks remain unchanged
in intensity after radiolabeling but show a small plasmon shift due to presence of
additional iodine molecules on the surface. [125I]-iodine labeled GNRs are stable for
weeks when stored in the refrigerator.
The washing process using centrifugation is critical. Uncompleted centrifugation
causes loss of radioactive GNRs in decanted supernatant, resulting in low radiochemi-
cal yields. On the other hand, the chance of irreversible nanorod aggregation increases
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Figure 5.1: UV-Vis of GNRs before and after labeling with 125I
when centrifugation period is extended. A series of experiments were performed to
investigate and optimize the conditions. To minimize variations, radiolabeled GNRs
were initially washed twice to remove free radioactive iodide and then dispersed in
deionized water. Table 5.1 summarizes the percentage of radioactivity collected in
pellets after centrifugation for various time periods. It should be noticed that a cen-
trifugation time of 30 minutes at 5000 rpm is necessary to recover all GNRs. However,
the possibility of failure to deliver desired product would then be over 30% due to
irreversible nanorod aggregation. Therefore, one washing using 15 minutes centrifu-
gation was applied for subsequent animal studies. No further washing will be needed
due to high affinity of iodide ions to GNRs.
Injectable doses for animal studies were prepared by mixing 0.5 mL of [125I] sodium
iodide with desired activity and 0.1 mL of GNRs (1012 rods/mL) for 5 minutes, and
then centrifuging at 5000 rpm for 15 minutes. The supernatant was decanted and
pellets were re-dispersed in 0.1 mL of fresh sterile filtered deionized water.
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Table 5.1: Summary of centrifugation for various periods
5.3.2 Stability of GNRs in blood circulation
The stability of injected GNRs within body is a key issue for successful targeting
of GNRs because they must be able to circulate in the blood long enough to find their
targets.132 However, the RES of the body filters nanoparticles from blood circulation
based on their size and surface characteristics.76,117 Rapid clearance of nanoparticles
from blood limits their targeting capabilities. Polyethylene glycol (PEG) has well-
established “stealth” properties that can shield nanoparticles from fouling by serum
proteins (opsonization) and reduce their rate of clearance by the RES.117,131 The
beneficiary effects of PEGylation on the clearance time of injected nanoparticles have
been demonstrated.132,140 Therefore, we synthesized three different kinds of GNRs,
normal bare GNR, PEGylated GNR with PEG 5,000 mol. wt. and PEG 20,000 mol.
wt., and examined their stabilities in blood circulation.
To determine the circulating time of gold nanorods, we assayed blood samples
from rats using γ-scintigraphy. The time-activity curves are shown in Fig. 5.2, and
indicate significant differences between bare GNRs and PEGylated GNRs. Injected
bare GNRs were cleared out from blood circulation within 10 minutes, while greater
than 50% of PEG coated GNRs remained in the blood after 4 hours. This is in good
agreement with previous studies which have shown that a surface brush layer of PEG
reduces the adsorption of blood RES factors to the particle surface hence decreasing
the rate of particle clearance.76,141 We have also found that it is irrelevant whether
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Figure 5.2: Blood time-activity curves
5,000 or 20,000 molecular weight is used.
The blood assay method described above is easy and reliable, providing initial
information of novel gold nanorods in biosystems. The γ-scintigraphy is highly sen-
sitive. Only a low dose of radioactivity has to be administrated and a small amount
of blood sample needs to be drawn for measurement. This simple assay would be the
first step for screening any newly designed target-specific GNRs.
5.3.3 Long-term biodistribution using γ-imaging
The next experiment evaluated the relatively long-term biodistribution in rat for
up to 6 days using γ-imaging. The same group of animals used for blood assays were
imaged at set times between blood sampling. Each image was acquired in 5-minute
on an anesthetized rat placed in anterior position over the parallel-hole collimator of
a Gamma Imager. Radioactivity was then quantified by drawing regions of interest
(ROI). For each animal, ROIs were drawn around the liver/spleen and heart/lung
and were saved to be re-used systematically for longitudinal follow-up. Figure 5.3
shows typical rat gamma images.
The linearity and precision of gamma detection were determined by scanning a
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Figure 5.3: Gamma images at different post-injection time. The upper three images
are from a rat injected with PEGylated GNRs. The lower three images are from a
rat injected with bare GNRs.
series of standards with known radioactivities. The standards were prepared by serial
dilution of a 125I-GNRs injection sample. Each standard was imaged for 5-minute
acquisition 8 times in various positions over the parallel-hole collimator. Radioactiv-
ity was then quantified by drawing regions of interest around the standard. Figure
5.4 shows good correlation between radioactivities counted by a Capintec well and
radioactivities measured by scintigraphic acquisition of the Gamma Imager. The co-
efficient of determination (R2) value was greater than 0.99, indicating accurate and
reliable measurement. The exact position of the sample on the camera head was
shown to be irrelevant. Radioactivities in liver/spleen and heart/lung determined by
the Gamma Imager were converted to injection dose based on this standard curve.
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Figure 5.4: 125I-GNRs standard curve
The uptakes of liver/spleen and heart/lung were then normalized to % of the injected
dose for each animal. Results are shown in Fig. 5.5. Uncoated bare gold nanorods
were found accumulated quickly in the liver and spleen area within 5 minutes. It
should be noted that, for bare GNRs, radioactivity was retained in the liver and
spleen for days. In contrast, PEG coated gold nanorods remained in the blood pool
for much longer period, but the long term accumulation was minimal in liver and
spleen area.
The liver/spleen and heart/lung areas were chosen as regions of interest because
GNR particles accumulate in the liver and spleen when they are removed from blood;
while they can be seen in the heart and lung when they are still freely circulating in
the blood. Figure 5.5 shows the significant differences of uptakes between bare GNRs
and PEGylated GNRs, and more importantly, the distinct metabolism pattern. The
bare gold nanorods were retained in the liver and spleen for days. This indicates
that bare metal particles are broken down and cleared from the body with difficulty.
In contrast, PEG coated gold nanorods remained in the blood pool for much longer
period, but the long term accumulation was minimal in liver and spleen area. The
observed efficient metabolism clearance pattern provides evidence that PEGylated
GNRs have low cytotoxicity and are more biocompatible within the body. They
are hence ideal candidates for target-specific duel agents for diagnostics and selective
photothermal therapy. The trends described here need to be tested in more detail with
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Figure 5.5: Activities in liver/spleen and heart/lung vs. time
a wider range of gold nanorods and will be reported in due course. This methodology
provides a highly efficient tool for monitoring in vivo behaviors of virtually any gold
nanocolloids.
In addition, we have successfully utilized GNRs to enhance the contrast in photoa-
coustic tomography (PAT).37 We expect that radioisotope labeled GNRs can lead to
the development of dual-modality imaging with the combination of nuclear imaging,
like SPECT or PET, and PAI. Furthermore, it is hopeful that radiolabeled GNRs
will become an efficient therapy agent with the combination of the power of radiation
therapy and photothermal therapy.
5.4 Conclusions
We have optimized the radiolabeling procedures, facilitating reproducible and
reliable production of injectable doses for animal studies. This simple setup can
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be further developed to deliver injectable dose for clinical application. GNRs were
successfully visualized by Iodine-125 tag allowing highly sensitive detection. The
blood assay method described here is easy and reliable, providing initial informa-
tion of novel gold nanorods in biosystems. Longitudinal biodistribution studies have
been performed repeatedly in the same animal, therefore decreasing sources of inter-
individual variations and also being beneficial in terms of animal cost and ethical
practice. Comparing with the previously reported methods, the methodology devel-
oped here provide a highly efficient and universal protocol for monitoring in vivo
behaviors of gold nanoparticles, GNRs, and other noble metal nanocolloids.
The preliminary animal results are very promising. PEGylated GNRs are ideal
candidates for target-specific duel agents for diagnostics and selective photothermal
therapy. With this powerful tool in hand, more work can be done to advance GNR
technology to a level for clinical use in regards to clearance, safety, efficacy of deliv-
erance and targeting. Encouraged by the preliminary study reported here, further
investigations of GNRs with various sizes, shapes, and different conjugates are in-
vestigation. Radiolabeled gold nanorods hold promise to enable the development




Targeted Gold Nanoparticles Enable Molecular
CT Imaging of Cancer
6.1 Introduction
Imaging plays a critical role in overall cancer management: in diagnostics, staging,
radiation planning, and evaluation of treatment efficiency. Standard clinical imaging
modalities such as computed tomography (CT), magnetic resonance imaging (MRI),
and ultrasound can be categorized as structural imaging modalities; they are able
to identify anatomical patterns and to provide basic information regarding tumor
location, size, and spread based on endogenous contrast. However, these imaging
modalities are not efficient in detecting tumors and metastases that are smaller than
0.5 cm and they can barely distinguish between benign and cancerous tumors.142
Molecular imaging is an emerging field that integrates molecular biology with in
vivo imaging in order to gain information regarding biological processes and to iden-
tify diseases based on molecular markers, which usually appear before the clinical
presentation of the disease. Currently, positron emission tomography and single pho-
ton emission tomography are the main molecular imaging modalities in clinical use,
however, they provide only functional information regarding molecular processes and
metabolites, which is indirect and nonspecific to distinct cells or diseases.143,144
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Recently, various types of targeted nanoprobes have been developed for optical
and MRI molecular imaging such as superparamagnetic nanoparticles;145–148 quantum
dots,149–151 and gold nanoparticles as cancer optical imaging probes.152–154 CT is one
of the most useful diagnostic tools in hospitals today in terms of availability, efficiency,
and cost. Currently, CT is not a molecular imaging modality since relevant targeted
and molecularly specific contrast agents have not yet been developed. Present CT
contrast agents are predominantly based on iodine containing molecules, which are
effective in absorbing X-rays; however, they are nonspecifically targeted because they
cannot be conjugated to most biological components or cancer markers and they allow
only very short imaging times due to rapid clearance by the kidneys.
Figure 6.1: First ever medical X-ray image (1895) taken by Roentgen. “Hand with
Ring” print of Wilhelm Roentgen’s first medical X-ray, taken on 22 December 1895.
It dramatically showed the bones of her fingers; however the real size of her finger’s
soft tissue could be garnered from the clearly visible gold ring on her finger. Likewise,
below we show that ringing the tumor cells with gold nanoparticles makes it effectively
more visible to CT. Note that the size of the ring maps the width of the finger’s soft
tissue. Radiology Centennial, Inc. copyrighted in 1993.
Gold induces a strong X-ray attenuation, as was first demonstrated, inadvertently,
by Wilhelm Roentgen, in the first X-ray human image (Fig. 6.1). Gold nanoparticles
have, in addition, unique physical, chemical, and biological properties, which make
them an ideal candidate for CT contrast agents. The ability of CT to distinguish
between different tissues is based on the fact that different tissues provide different
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degrees of X-ray attenuation, where the attenuation coefficient is determined by the
atomic number and electron density of the tissue; the higher the atomic number
and electron density, the higher the attenuation coefficient. The atomic number and
electron density of gold (79 and 19.32 g/cm3, respectively) are much higher than those
of thecurrently used iodine (53 and 4.9 g/cm3). Note that for CT imaging the total
amount of gold per unit volume (voxel) is the only important parameter regardless
of the shape of the particles. In addition, gold nanoparticles provide a high degree
of flexibility in terms of functional groups for coating and targeting and have also
proved to be nontoxic and biocompatible in vivo.155,156
Recent progress toward nanotechnology based CT imaging has been made by
Hainfeld et al ;157 they demonstrated the feasibility of gold nanoparticles to induce
in vivo vascular contrast enhancement in CT imaging, however the gold particles
were not targeted as they were not conjugated to specific biomarkers. More recently,
hybrid nanoparticles such as antibiofouling polymer-coated gold nanoparticles,158,159
gadolinium-coated gold nanoparticles,160 PEG-coated nanoparticles,161 and polymer-
coated Bi2S3 nanoparticles
162 have been developed as vascular CT contrast agents.
In this study, we describe a new platform for in vivo CT molecular imaging based on
new class of immuno-targeted gold nanoprobes that selectively and sensitively target
tumor specific antigens. These gold nanoprobes form a concentrated assembly on
the cancer cells, yielding a distinguishable X-ray attenuation, which is not typical for
nondecorated cells or tissue. This transforms the targeted cancer into highly distinct
and easy to diagnose features.
While a CT molecular imaging agent would potentially have broad applicability
for many cancer types, for this research we have chosen to work with head and neck
cancer, which is the fifth most common cancer worldwide.163 Squamous cell carci-
noma (SCC) represents more than 90% of all head and neck cancers. Many SCC of
the head and neck present as advanced tumors for which the true extent is difficult
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to determine from present CT and physical examination. Cure rates for oral cancers
have declined in recent years,164 and better diagnostic tools are needed for accurate
staging and discovery of tumor extent. Previously it has been demonstrated that
SCC is characterized by significant overexpression of the A9 antigen,165 which is also
called the α6β4 integrin,166 and that there is a strong correlation between the A9
expression level and metastatic behavior.167 It has also been demonstrated that the
UM-A9 antibody can home onto SCC tumors in vivo.168 An additional reason for
choosing head and neck cancer was because one of its major diagnostic challenges
today is a reliable detection of involved lymph nodes because their status is one of
the most important prognosis predictors and is also critical for appropriate treatment.
However, assessment of lymph nodes based on structural imaging features is limited
in sensitivity and specificity and fails to distinguish between non-neoplastic and ma-
lignant processes. These limitations lead to the routine performance of prophylactic
procedures such as extensive neck dissection and radiation and, on the other hand,
a lack of treatment for undiagnosed small metastases, which is the first cause of the
reappearance of cancer. Hence, the development of more sensitive in vivo imaging
techniques is of major importance and could substantially improve head and neck
cancer diagnosis, treatment, and potential cure.
In these experiments, we synthesized GNRs and conjugated them with UM-A9
antibodies, which home specifically to SCC head and neck cancer.168 We examined
their feasibility to effectively induce contrast enhancement in CT imaging, as a specific
and sensitive targeted probe in head and neck cancer. Note that for CT imaging
the total amount of gold per unit volume (voxel) is the only important parameter,
regardless the shape of the particles. GNRs are more advantageous in comparison
with spherical nanoparticles because they offer a complementary method of detection
for some cancers based on their IR adsorption.154,169 Most importantly, in comparison
with other techniques utilizing optical properties of GNRs, CT scans are not limited
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by the depth of cancer in the tissue.
6.2 Experimental section
6.2.1 GNRs synthesis and conjugation
GNRs were synthesized using the seed mediated growth method.57 The mean
length was 45 nm and the mean diameter was 15 nm with gold concentration of
2.5 mg/mL. Antibody conjugation: The bioconjugation of the GNRs to the UM-A9
antibody was achieved according to the method described by Kim et al.38 Briefly, a
layer of biocompatible36,37,170 PAA was adsorbed onto the surface of GNRs followed
by addition of EDC/NHS. PAA-coated nanorods were dispersed in 1 mL of PBS (pH
6.0) buffer, followed by 100 µL EDC and 100 µL of 0.2 M NHS mixture to provide
active sites on GNRs that undergo amidation reaction with the antibodies. The
amount of antibody added is 20 µg per 1.96 mg of molecular gold. The mixture was
stored overnight in refrigerator at 4 , followed by centrifugation and redispersion in
ultrapure water to remove unbound antibody in the solution.
Cell culture: UM-SCC-1 and UM-SCC-5 human head and neck cancer cell lines
and the negative control samples of fibrosarcoma (UM-FS-1) and melanoma (UM-Mel-
1), which are known not to express the A9 antigen, were cultured in DMEM media
supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 100 units/mL
penicillin, 100 µg/mL streptomycin sulfate, and 292 µg/mL L-glutamine (all from
InVitrogen, Carlsbad CA).
Cells-GNRs binding: One milliliter of cell suspension (106 cells/mL) was mixed
with 1 mL of antibody-coated GNRs solution (2.5 mg/mL) and allowed to interact
for 90 min at room temperature. Then, the solution was 3 times centrifuged at 1000
rpm for 5 min to wash out unbound antibody from the GNRs-antibody complexes;
after each centrifugation step, the mixture was redispersed in PBS solution (1 mL
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total volume).
6.2.2 CT scan experiment
All scans were performed using clinical CT at 80 kVp (GE Lightspeed QX/I;
General Electric, Waukesha, WI). The suspensions, in cuvettes, were scanned using a
shaped Styrofoam assembly to hold the samples in place. Two SCC human head and
neck cancer cell lines (106 cells/mL) were used; oral cancer UM-SCC-1 and larynx
cancer UM-SCC-5. Both cancerous cell lines were shown before to have a significant
overexpression of the A9 antigen.165 CT imaging was performed on the SCC cells,
which were targeted with the UM-A9 antibody-coated GNRs. The following negative
control experiments were performed: (A) CT imaging of the same head and neck
cancer cells (UM-SCC-1 and UM-SCC-5) in a suspension, without the addition of
nanoparticles, (B) CT imaging of the same head and neck cancer cells that were
targeted with GNRs that were coated with antibodies that do not match with the
SCC cells (KHRI-3), and (C) CT imaging of noncancerous cells (normal fibroblast
cells) and of other types of cancer cells (melanoma) that were targeted with the UM-
A9 antibodies-coated GNRs. CT imaging of a solution of bare GNRs (suspended in
water, without any cells) provides the positive control.
6.3 Results
6.3.1 CT scan
The attenuation values (HU) that were obtained from the CT imaging are shown in
Fig. 6.2. As shown in Fig. 6.2, the change in the attenuation coefficient (with respect
to water) of the SCC cancer cells that were targeted by the A9 antibody-coated GNRs
is over 5 times higher than that of the nontargeted SCC cancer cells (32 and 28 HU vs
168 and 172 HU, respectively). This demonstrates that the GNRs were attached to the
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Figure 6.2: CT attenuation (HU) of SCC head and neck cancer cells and positive and
negative control samples. Bar graph with standard deviation of 3 samples: larynx and
oral cancer cells that were targeted with A9 antibody-coated GNRs, larynx and oral
cancer cells without GNRs, larynx and oral cancer cells targeted with nanorods that
are coated with nonmatching antibodies (KHRI-3); normal fibroblast and melanoma
cells targeted with A9 antibodies, bare GNRs in water solution (2.5 mg/mL), and
water
cancer cells with high density, yielding a distinguishable CT attenuation number that
is higher than that for typical soft tissue (typical attenuation values for solid tissue
are in the range of 0-50 HU), thus making the targeted cells detectable in sufficient
concentration. The attenuation values observed for the negative control samples that
were targeted with GNRs (larynx and oral cancer cells targeted with nanorods that
are coated with nonmatching antibodies and normal fibroblast and melanoma cells
targeted with A9 antibodies) revealed relatively low nonspecific binding (58, 54, 50,
62 HU, respectively) and demonstrate that head and neck tumors may show a likely
enhancement of 3-4 times the local contrast of nontargeted tissue in vivo. Such a
specificity and local enhancement is consistent with a previous study investigating
the potential use of UM-A9 as a radiolabeled imaging agent for human squamous
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carcinoma tumors in vivo.168 The attenuation value observed for the positive control
sample, the bare GNRs, is 158 HU; this high number was expected because the sample
contained a high concentration of gold (2.5 mg/mL).
In these experiments, we tested 1 mL samples that contained 106 SCC cancer
cells. Assuming the size of one SCC cancer cell is approximately 10 µm, there may
be sufficient differential signal from tumors as small as 1 mm3 to provide detectable
contrast, nearly at the limit of resolution for clinical CT scanning. Another important
parameter that should be noted is the high differential contrasts that have been
obtained in the above experiments. The signal (HU obtained from the targeted SCC)
is significantly higher than the background value (defined as the HU obtained from the
control experiments). The enhancement of local signal increases local CT attenuation
above the normal values for soft tissue, thus providing encouraging initial indications
that sufficient specificity can be obtained in in vivo experiments.
6.3.2 Light scattering images of targeted and nontargeted SCC head and
neck cancer cells
SCC head and neck cancer cells that were targeted with UM-A9 antibody-coated
GNRs and SCC that were incubated with nonmatching antibodies (R-KHRI-3) coated
GNRs were placed on a slide for dark field microscope imaging.
Figure 6.3 shows, for the scattering images, clearly distinguishable differences be-
tween the specifically and selectively targeted SCC cells and those that were exposed
to nonmatching coated GNRs. The SCC cancer cells (oral and larynx cancer) that
were targeted with the nonmatching antibody-coated GNRs yielded only a small
amount of scattered light, resulting from the nonspecific binding. Yet, these images
clearly illustrate that only the correctly conjugated nanoparticles bind specifically,
with high concentrations, to the surfaces of the SCC cells.
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Figure 6.3: Dark field microscope images of SCC head and neck cancer cells. Dark
field microscope images of SCC head and neck cancer cells (oral cancer upper im-
ages, larynx cancer lower images) after incubation with nonmatching antibody-coated
GNRs (left) vs matching UM-A9 antibody-coated GNRs (right). Scale bar: 10 µm
6.4 Conclusions
In conclusion, these proof of principle experiments demonstrated that we may be
able to identify, through CT scans, the existence of SCC cancer cells; the concentrated
assembly of gold nanoparticles that form exclusively on the targeted cancer cells yield
a strong selective X-ray attenuation that is distinct from the attenuation obtained by
identical but untargeted cancer cells or by normal cells.
We expect that the CT molecular imaging technique will revolutionize modern
head and neck cancer diagnosis and staging, by allowing reliable and sensitive de-
tection of lymph nodes and other metastasis, which are not available today. This
might also prevent or minimize the now routinely performed neck dissection, which
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is associated with considerable morbidity. The importance of such a technique is fur-
ther reinforced because of the vast availability and the extensive use of CT in clinics
today and will provide the ability to perform simultaneously macroscopic (CT) and
microscopic (molecular based CT) imaging.
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CHAPTER VII
Optical Emission and Energy Transfer in
Nanoparticle-Nanorod Assemblies: Potential
Energy Pump System for Negative Refractive
Index Materials
7.1 Introduction
One of the most fascinating types of metamaterials that is actively researched is
negative refractive index materials (NIMs). Early theoretical discussions by Veselago
showed that an isotropic media with both negative permittivity, ε, and permeability,
µ, will exhibit a negative refractive index along with several other interesting proper-
ties.171 However, such materials remained a curiosity for decades because no naturally
occurring materials exhibit simultaneous negative µ and ε over a common frequency
range. Recent theoretical demonstration by Pendry showed that an ideal Veselago
lens (flat slab in vacuum with ε = µ = −1) can not only focus light from an object
to form an image but can do so with subwavelength resolution (∆x < λ).1 Such lens
has been termed the “perfect lens” and has created a new surge of interest in the
development of artificial metamaterials with negative refractive index. NIMs have
also been suggested as novel materials for usage in biological and security imaging,
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biomolecular fingerprinting, remote sensing, cloaking devices, and guidance in zero
visibility weather condition.43–45
The two most common approaches to fabricate NIMs take advantage of photonic
crystals3,172–174 or plasmonic periodic metal dielectric nanostructures.175–177 NIM
photonic crystals are based on the excitation of photonic band gaps with negative
slope to support negative phase velocity in the medium and are limited in their per-
formance due to scattering from surface imperfections. In metal-dielectric nanostruc-
tures the displacement currents near plasmonic resonances are used to produce both
negative permittivity and negative permeability. One-dimensional gold and silver
nanostructures in various arrangements have been theoretically and experimentally
shown to have negative refractive index.178 Importantly, operating near plasmonic
resonances in metallic NIMs makes their response strongly dispersive and lossy;179
thus, restraining the restoration of near field modes which are required for sub wave-
length resolution in the image. One way to reduce losses in metallic systems is to
operate away from the resonances,180 however this would weaken the diamagnetic
response of the medium potentially causing it to no longer have the effective negative
permeability. The other way is to compensate the losses by providing a gain medium.
The conventional way of adding a gain medium is by sandwiching a 2D layer be-
tween the NIM, but this requires an impedance match at the interface to avoid losses
by reflection.181,182 Submerging entire metallic nanoparticles (NPs) in dye molecules
which act as a gain medium has also been suggested.183 Dyes, however, have limited
lifetime and bleach rapidly. As well, there are inherent optical limitations related to
Stocks shift in organic dyes that limit their applicability to NIMs.
In this paper, we demonstrate that semiconductor NPs assembled with metal-
lic nanorods or similar optical media can be used as a potential gain material for
NIMs. Both experiments and corresponding theoretical calculations describing cou-
pled optical oscillators in semiconductor (exciton) and metal (plasmon) clearly in-
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dicate that the excitonic energy of NPs can be funneled into the plasmon of gold
nanorods (GNRs). The actual manufacturing of such assemblies was accomplished
using fairly universal the biotin-streptavidin (B-SA) bioconjugation strategy between
CdTe NPs and GNRs. Strong quenching of CdTe NPs, which indicates energy trans-
fer into GNRs was observed. Given sufficient intensity and coherence of the excitation
of NPs away from the resonance band of GNRs, the energy transfer can compensate
for losses in NIMs.
7.2 Experimental section
7.2.1 Materials
Hexadecyltrimethylammonium bromide (CTAB), silver nitrate, ascorbic acid, sodium
borohydride, gold(III) chloride, L-cystine, thioglycolic acid (TGA) were purchased
from Aldrich and used without further purification. Deionized water (Barnstead, E-
pure system) with 18 MΩ was used in preparation of solutions. Streptavidin (SA)
and D-biotin (B) were obtained from Aldrich. 1-Ethyl-3-(3-dimethylamino propyl)
carbodiimide hydrochloride (EDC) and N-hydroxy-sulfosuccinimide (NHS) were pur-
chased from Aldrich and Merck for bioconjugation, respectively.
7.2.2 Synthesis and bioconjugation of GNRs
GNRs of average aspect ratio 3.7 (length 48 nm and width 13 nm) were synthesized
by a method described elsewhere.57,92 Synthesized GNRs were purified by removing
excess salts and stabilizer using centrifugation and redispersion into deionized water.
The GNRs are dispersed in deionized water to achieve a concentration of 10−8 M of
GNRs in the solution. CdTe NPs were synthesized with L-cystine stabilizer (average
diameter 3 nm) for bioconjugated assembly as reported previously.184 The particles
were used as synthesized (average concentration 10−5 M of NPs) without any fur-
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ther purification. Binding of biotin to L-cystine NPs is performed as described in
literature.185,186
A layer of poly(acrylic acid) (PAA) is adsorbed onto the surface of GNRs by
adding 1.5 mL of 1 mg/mL PAA solution to 1 mL of the stock gold GNRs solution.
The mixture is stirred for 3 h followed by two cycles of centrifugation and redisper-
sion to remove excess PAA in the solution.187 The layer of PAA provides the -COOH
functional group required for the conjugation. The PAA coated nanorods are dis-
persed in 1 mL of PBS 6.0 buffer solution followed by the addition of 100 µL of 0.2
M EDC and 100 µL of 0.2 M NHS. After 20 min, the reaction mixture is added with
20 µL of SA. The EDC/NHS mixture forms an active ester intermediate with the
gold nanorods which undergoes amidation reaction with the -NH2 group in SA to
yield the conjugate. The reaction mixture is stored in refrigerator at 4  overnight
following centrifugation and redispersion in buffer to remove the unconjugated SA.
Photoluminescence spectrums were recorded using Fluoromax-3 spectrofluorometer
(Jobin Yvon/SPEX Horiba, NJ). UV-visible absorption spectra were recorded using
Agilent (former HP) UV-vis spectrophotometer.
7.3 Results
We used two approaches for the preparation of NP-GNR complexes: electro-
static and bioconjugation. In the electrostatic method of assembly we used positively
charged GNRs and negatively charged NPs bearing thioglycolic acid as a stabilizer.
Electrostatically bound structures were appealing to us because they can potentially
reduce the gap between the nanoscale building blocks, and thus, increase the reso-
nance amplitude in exciton-plasmon hybrid states. However, NP-GNR superstruc-
tures assembled electrostatically displayed approximately an order of magnitude lower
efficiency of NP→GNR energy transfer than protein-bound systems potentially due
to the dynamic nature of the electrostatic assemblies where NPs migrate in and out
67
of the range of plasmon-exciton interactions with GNRs. Thus, all the data presented
here refer to the system with B-SA linker.
Figure 7.1: (A) TEM image of bioconjugated assembly, ratio of NPs/GNR=25. (B)
HRTEM image showing the lattice structure of NP bioconjugated to GNR
Structure of the NP-GNR Complexes. Bioconjugates of NPs and other nanocol-
loids bearing biological groups with strong mutual affinity allow one to create so-
phisticated NP assemblies.60,188–191 As such, due to specific binding between SA and
B, mixing of GNR-SA and NP-B leads to superstructures with NPs attached to the
surface of GNRs (Fig. 7.1). The same conclusion can be reached from the study of
electrokinetic ζ potentials of the nanocolloids (Table 7.1). As the ratio of the number
of CdTe NPs per GNR (i.e., NP/GNR ratio) increases, the zeta potential gradually
changes from positive to negative. The change of sign of zeta potential is reflective
of the increase of the density of NPs attached to GNRs. The separation between the
NP and GNR in bioconjugated structures is due to the presence of bilayers of CTAB,
streptavidin-biotin and L-cystine.
Assuming the simple case of attachment via SA-B connection, the distance be-
tween the center of the NPs and the surface of the GNR is estimated to be ∆BA=6.5
nm. Distances between the two components are established from TEM images at
higher magnification to give an average NP-GNR distance of 5 nm which coincides
with the estimates above quite well. In case of formation of additional shells of NPs
attracted by, for instance, strong van der Waals forces to the initial coating of NPs,
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Table 7.1: Lifetime Values and Electrokinetic (ζ) Potentials for Bioconjugated As-
sembly at Various NP/GNR Ratios
the distance between the GNR surface will increase by a few more nanometers de-
pending on the NP layer geometry. The signs of NP clustering around GNRs beyond
a simple monolayer can be seen in Fig. 7.1(A). This process can be treated as if the
self-assembly of the first layer catalyzes the adherence of the NP in the second layer.
At the same time it is self-limited due to strong repulsion of similarly charged NPs
in the shells. The same processes are observed during the layer-by-layer assembly of
NPs.
One also needs to remember that the NP-GNR bioconjugates are 3D structures,
which creates difficulties in traditional TEM imaging. Bringing both components of
the assemblies, NPs and GNRs, in focus at the same time, becomes more difficult
than for much simpler 2D arrangements of GNRs or NPs separately. However, we
were able to do it when both building blocks are properly positioned. In Fig. 7.1(B)
one can clearly distinguish the lattice planes corresponding to CdTe particles and
GNR. The CdTe NPs show a lattice spacing of 0.249 nm which corresponds to the
(111) plane of CdTe nanocrystal with a literature value of lattice spacing of 0.229
nm.192 The distribution of the NPs along the length of the rod is fairly random;
no preference is given to the ends of the rods or their sides (Fig. 7.1). We also see
evidence (Fig. 7.1(A)) of NP clustering around the GNRs and formation of double
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shells. The primary bond between the first layer of NPs and GNRs is of SA-B nature,
while subsequently the particles in the secondary shell are attached by nonspecific
interactions.
7.3.1 Optical properties
Based on previous studies,60,185,188–191,193 NP-GNR distances observed in Fig. 7.1
are expected to result in strong interactions between exciton and plasmon states in
the semiconductor and metallic particles, respectively. This interaction can result in
both luminescence enhancement194,195 as well as quenching.60,196 NP superstructures
studied previously included the assemblies of CdTe NWs and GNPs.193 The general
geometrical configuration of the superstructure in the present case is similar to those
reported before60,185,190,193 with the exception that the symmetries CdTe and Au
components are switched, i.e. the axial rod like structures here are made from metal
as opposed to the semiconductor wires in the previous publication. This results
in radical differences in optical behavior of the superstructures. In the present case,
when the rods are made from gold, we observe very strong quenching of CdTe excitons
that are attributed to energy transfer from NP to GNRs via a resonance state (Fig.
7.2(A-C)), as opposed to the enhancement of exciton emission due to coupled field
stimulation from Au NPs observed previously.
The quenching of NP luminescence in bioconjugated superstructures progresses
over a period of 30 min, following the typical B-SA binding kinetics.60,73,197 Upon
addition of NP-B into a solution containing GNR-SA we find that initially there
is a fast drop in PL intensity within first 3 min, followed by much slower gradual
decrease over the next 27 min. The early stages of the kinetic curve should cover
mostly the formation of B-SA links, while the later stages should mostly describe
attachment via nonspecific interactions. At the moment these two parts are difficult
to separate. However, more detailed investigation of this process will make it possible
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Figure 7.2: (A) Consecutive fluorescent spectra for the formation of NP-GNR bio-
conjugated assembly with NP/GNR=125. (B) Consecutive fluorescent spectra for
the formation of NP-GNR bioconjugated assembly with NP/GNR=12.5. (C) Change
of lifetime values of NPs during the period of formation of bioconjugated NP-GNR
assembly. (D) UV-vis of GNR-SA before and after assembly with NP-B. Excitation
wavelength 350 nm.
when such data might be necessary. Note there is an increase of the background
signal in the “wings” of the luminescence peak for the later stages of assembly, which
is attributed to stronger scattering of the assembled structures. When one compares
quenching data from the two systems with NP/GNR ratios different by 10 times
(Figure 7.2(A)&(B)), the kinetics becomes about 10 times slower in accordance with
general theory of reaction rates ∂[NP-GNR]/∂t=k[NP][GNR], giving the degree of
quenching over a period of ca. 30 min for NP/GNR=12.5 approximately equal to
that observed for 3 min for NP/GNR=125. Importantly, for both NP/GNR ratios
the final state is almost complete quenching of NP luminescence (Fig. 7.2(A)&(B)).
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The CdTe fluorescence peak spanning 480 to 580 nm overlaps with the transverse
plasmon resonance (480-550 nm) of the GNR. The coupling of excitons from NP with
plasmons is believed to be able to funnel energy into the GNR.198 NPs are excited
in the near UV wavelengths and would interact minimally with the incident light
(optical wavelengths) and avoid any undesirable effects on the effective properties
of the material at optical wavelengths. The presence of CdTe NPs around GNR,
however, slightly dampen and broaden the plasmonic response of the GNRs (Fig.
7.2(D)), which may or may not be significant for actual NIM structures. Slight
broadening of the plasmon resonance may actually be advantageous for NIMs as it
provides a broader wavelength range over which the NIM response could be realized.
The broadening of the plasmon peak and the presence of semiconductor NPs at the
interface may actually serve as a convenient control parameter to vary the degree of
resonance/ off-resonance excitation for NIM structures.
The conjugated NPs remain stable in solution and show same plasmon absorption
as in Figure 7.2(D) for 7 days. The plasmonic absorption starts decreasing after 7
days and the solution shows aggregated particles after 12 days which may be caused
due to protein denaturation. Since the NP-GNR assembly is robust one can use these
structures by depositing them onto substrates or thin films. The stability period is
also sufficient to carry out any polymerization reaction necessary to permanently fix
the assemblies.
The effect of superstructure formation on the lifetime of CdTe excitons was also
measured (Table 7.1 and Fig. 7.2(C)). For small NP/GNR ratios this is fairly dif-
ficult to do due to low overall luminescence and strong quenching, but for ratios in
the range of 333-1000 the lifetime, τ , can be measured during the assembly process.
As expected, formation of the NP-GNR superstructure results in significant decrease
of the emission lifetime because of the NP→GNR energy transfer processes. Larger
NP/GNR ratios results in slower kinetics which indicates the change in general kinetic
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description of the process for high concentrations of NPs and potential saturation pro-
cesses when the amount of NPs is sufficient to occupy all available surfaces on GNRs.
Simple geometrical calculations for closely packed structure of CdTe NPs on GNRs
with the dimensions used here correspond to 70 NPs per one GNR, however, appar-
ently greater number of NPs may cluster around the GNRs in 2 or more shells due
to the nonspecific clustering of NPs. We observed complete quenching as NP/GNR
ratio reached 25. So, we were unable to experimentally measure the lifetime of the
assembly at this ratio because of the low luminescence intensity. We use the Stern-
Volmer quenching kinetics (Eq. 7.1) to fit the experimental data from higher NP/NR
ratios and obtain theoretical value of lifetime at lower NP/GNR where experimental
data is difficult to measure.
τ 0
τ
= 1 + Kaτ
0[Q] (7.1)
Where Ka, is the bimolecular reaction rate constant for the elementary reaction of
Figure 7.3: Stern-Volmer fit of the experimental data given in Table 7.1
the excited state with the particular quencher Q, τ 0 is the lifetime in the absence of a
quencher (i.e., absence of NR in our case) and τ is the lifetime in presence of quencher
73
concentration [Q]. Concentration of the quencher [Q] i.e., GNR is calculated by their
final concentration in the solution. Linear fit of the experimental data gives us the
value of Kaτ
0=1.257 mol−1. The value of lifetime obtained for NP/GNR=50 and 25
corresponding to [Q] = 33.33×10−11 M and 66.66×10−11 M gives us a lifetime value
of 0.621 ns and 0.314 ns respectively.
The lifetime data shown in Table 7.1, the data in Fig. 7.2(C), and the quantum
yield for the NPs equal to Y=0.115 were used as input parameters in the theoretical
calculations described below as well as in the ensuing discussion.
7.3.2 Blue shift of emission peak
Interestingly, we observe a noticeable blue shift in the emission spectra of NPs by
∼5 nm as formation of the bioconjugated assembly proceeds (Fig. 7.2(A),(B) and
7.4).
Figure 7.4: Position of the maximum of emission peak during the period of formation
of two bioconjugated assemblies with GNR=125 (1) and GNR=12.5 (2)
This shift may come from the reduction of Coulomb binding energy, ECoulomb,
of an exciton in CdTe NPs due to an enhanced dielectric screening in a bioconju-
gated assembly according to the standard equation of quantum confinement effect in
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semiconductor NPs:
Eexc = Ebulk + h
2/2m∗d2 − ECoulomb (7.2)
where Eexc is the energy of emitted exciton considered to be equal to band gap energy
in the quantum confined state, Ebulk, is the band gap in the bulk state, h is Plank
constant, m∗ is the reduced mass of electron and hole m∗ = 1/me + 1/mh, d is the
diameter of the NP. Upon assembly, the Coulomb interaction between an electron and
hole inside CdTe NP becomes slightly lower since the average dielectric constant of the
surrounding increases due to the presence of the neighboring metal and semiconductor
NPs.
7.4 Theoretical model and Discussion
Quenching of emission and shortening of exciton lifetime in the NP-GNR super-
structures can be explained using a model based on the exciton-plasmon resonance
(Fig. 7.5) taking place when emission peak of excitons in NPs and adsorption peak
of the plasmons in GNRs display a spectral overlap. In a NP-GNR complex, oscil-
lators corresponding to excitons in NPs and plasmons in GNRs couple via simple
Coulomb forces. Since NP-GNR complexes are in liquid, they are randomly oriented
with respect to the incident electric field, ~E0 (Fig. 7.5(A)). To obtain analytical
estimates, we will treat GNRs as infinite cylinders. In addition, we will consider
here the near field regime where λ >> d is the wavelength of light and NP-GNR
distance, respectively. Considering the data in Figure 1, this assumption is certainly
valid.The electric field in the vicinity of infinite metal cylinder is described by the
potential: φ = − ~E0~r + (εAu − ε0)/(εAu + ε0) • (a2GNR/4ρ2) ~E0~r, where aGNR is the
GNR diameter, ρ is the distance to the GNR axis, and εAu and ε0 are the dielectric







, where ~E is the electric field in the vicinity of GNR and
Ω is the solid angle. Averaging over Ω is introduced to take into account random






= E20 [1 + (2/3)γγ
∗(a4GNR/d
4)], where γ = (εAu − ε0)/(εAu + ε0).
The intensity of emission from a CdTe NP is derived from the rate equations pub-
lished previously for molecular systems with fluorescent dyes.194Note that molecular
and nanoscale superstructures have an important difference. An excitation in molec-
ular systems is described by one exciton with a given direction of dipole moment. A
spherical NP has three optically active excitons with optical dipoles along x, y, and
z axes. Due to fast spin relaxation at room temperature, we can assume that optical
excitation creates almost equal populations of excitons with different orientation in
respect to a NP axis. Therefore, to calculate the resultant emission of a NP, we have
to take into account all three orientations of excitons. At room temperature, the
emission intensity of NP is given by188,199
Iemiss(λ1, λemiss) =
P(λemiss) • γ0rad•P(λ1)•I0abs
P(λemiss) • γ0rad + γ0non−rad + γtransfer(λemiss)
(7.3)






/E20 is the averaged field enhancement factor for a NP in
the vicinity of a GNR, and I0abs and γ
0
rad are the light absorption and radiative rates of
a CdTe NP in the absence of a GNR. The denominator in Eq. 7.3 represents the total
recombination rate of an exciton γrec = P (λemiss) • γ0rad + γ0non−rad + γtransfer(λemiss),
where γ0non−rad is the nonradiative recombination rate and γtransfer(ωemiss) is the rate
of NP→GNR energy transfer. The parameter P(λemiss) • γ0rad in Eq. 7.3 describes
the radiative emission rate of an exciton in a NP in the presence of a GNR. Similarly,
P(λ1)•I0abs is a metal-modified absorption rate of a CdTe NP. In particular, we can
see that the factor P(λ) is an important parameter of the system. From Eq. 7.3, we
obtain the ratio between emission intensities before and after conjugation:
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Figure 7.5: (A) Model of NP-GNR system. Red arrow shows the process of energy
transfer. (B) Calculated energy rate as a function of NP-GNR separation. (C and
D) Theoretical results for enhancement factor and emission ratio





γtransfer + γrad,av,0P(λemiss) + γnon−rad
(7.4)
where Ptot = P(λ1)P(λemiss) is the resultant field enhancement factor for the
emission; γnon−rad = (1 − Y) • γ0rec and γ0rad = Y • γ0rec where Y is the quantum
yield and γ0rec = 1/τ
0
rec is the recombination rate of excitons in NPs in the absence of
metal GNRs. The transfer rate γtransfer describes the process of Forster like energy
transfer NP→GNR (Fig. 7.5(A)). This process comes from the Coulomb interaction
between a photoexcited exciton in a CdTe-NP and plasmons in a GNR. A convenient
formalism to calculate the rate γtransfer is based on the response function.
188,199
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where εeff = (2ε0 + εNP )/3 and dexc is the exciton dipole moment and εNP is the
dielectric constant of CdTe. We note that the transfer rate in Eq. 7.5 was calculated
as an averaged transfer rate of three types of excitons in a CdTe NP: γtransfer =
(γtr,x + γtr,y + γtr,z)/3, where γtr,i is the transfer rate for the exciton with a dipole
moment in the i-direction.
For small distances (∆ < RGNR), γtransfer ∝ 1/∆3.200 For large distances (∆ >
RGNR), Eq. 7.5 is no longer applicable and γtransfer ∝ 1/∆5.190 Equation 7.5 was
used to obtain estimates for bioconjugated complexes with the following parameters:
aGNR=15 nm, RNP ≈ 1.5nm (CdTe NP radius) and ∆=6.5 nm (length of SA-B
linker length). Exciton emission from our CdTe NPs has the following characteristics:
τ 0rad=26.6 ns and Y≈0.115 (see above). The dielectric constant of the metal was taken
from the tables201 and the other dielectric parameters were chosen as εNP = εCdTe =
7.2 and ε0 = εwater = 1.8. The exciton dipole moment was estimated from the
radiative time: dexec= 0.53
◦
A. Results of calculations are summarized in Fig. 7.5(B-
D). For the assembly, we obtain an energy transfer time of 1/γtransfer ≈ 1.51ns.
The calculated lifetime of an exciton in the NP-GNR superstructure is 1/γ0rec =
1/(P · γrad + γ0non−rad + γtransfer) ≈ 1.4ns. Regarding the emission intensity, the
following emission ratio was calculated: A≈0.07. Overall, our theoretical data are
in qualitative agreement with the experimental data (Table 7.1 and Fig. 7.2(A-B)).
Importantly, our theory reveals microscopic mechanisms of energy exchange in the
NP-GNR assemblies. We note that the calculated exciton lifetime in the bioassembly
(1/γrec ≈ 1.6ns) is close to the observed lifetime (2 ns) for NP/GNR=125 from Table
7.1. However, the extrapolated lifetimes for very small NP-GNR ratios are essentially
78
shorter (Table 7.1). We see two possible ways to explain it: (1) extrapolation using
the Stern-Volmer kinetics is not always reliable or (2) there may be an additional
mechanism of quenching of emission in the system.
Considering the trend of experimental points in Stern-Volmer plot (Figure S1, Sup-
porting Information), which indicates that the for small NP/GNR ratios the lifetime
becomes shorter, we believe that additional mechanisms of energy transfer/quenching
are possible which can be represented by charge transfer reactions. Finally, the phys-
ical reasons why the lifetime strongly depends on the NP/GNR ratio should also be
discussed. In experiments (Table 7.1), we clearly see this tendency: the lifetime be-
comes strongly reduced with decrease of the NP/GNR ratio. Physically, this can be
explained in the following way: when NP/GNR> 70, NPs cannot form a single shell
around a GNR and arrange themselves in two or more layers. Moreover, even for
relatively small NP/GNR ratio, not all NPs may form a single shell and be very close
to the metal surface. Some of NPs may be on the top of other NPs (see Fig. 7.1).
This means that the average NP-GNR distance is dependent on NP/GNR ratio and
therefore, the NP-GNR transfer time becomes dependent on it too, becoming shorter
when smaller number of NPs is present (Stern-Volmer fit, Fig. 7.3). One can also
can notice that the blue shift in Fig. 7.4 is larger for NP/GNR=12.5; this behavior
is consistent with the same distance dependence as was described above for lifetimes.
For smaller NP/GNR ratio (12.5), the blue shift should be indeed larger since NPs
are located on average closer to the metal surface and the metal screening effect is
stronger. For the larger ratio (125>70), the blue shift should be smaller since the
average NP-GNR distance is increased. We also should compare the experimental
and theoretical emission ratios, A. For the assembled structures with NP/GNR=125,
we see a nice overall correspondence of theory and experiment: Atheory ≈ 0.07 and
Aexper ≈ 0.08. Finally we should note that the plasmon-induced field enhancement in
our system is small, Ptot ≈ 1. Therefore, the energy transfer process plays the main
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role and leads to strong emission quenching as opposed to emission enhancement.
7.5 Conclusions
We have demonstrated NP-GNR superstructures which can act as potential energy
transfer pumps and help reduce the absorptive metallic losses. Excitons created
optically in NPs become converted into plasmons in metal GNRs via the Forster
energy transfer mechanism and intermediate exciton-plasmon hybrid resonant state.
In this way, the plasmon population inside the metal component can be sustained via
off resonance light adsorption. The excitation wavelength of NPs can be far from the
plasmon resonance wavelength of GNR, say in UV absorption bands of CdTe, such as
350 nm as we used in this work, hence the emission of NP would interfere minimally
with the incident light at optical wavelengths unlike similar systems that can be
created from dyes. Additionally, the energy transfer in NP systems is likely to be more
efficient than in analogous dye-based structures due to better resonance conditions
with plasmons in GNRs and fast spin relaxation to match the required one for a
particular place on the GNRs. We see the need to reveal in greater detail the exciton-
plasmon interactions in semiconductor-metal assemblies with GNRs and potential
competing mechanisms of energy relaxation requiring single-particle spectroscopy and
pump-probe techniques.
As a part of the concluding remarks, we also want to make two points about appli-
cations of such systems for NIMs. (1) The GNR from gold or other metal will likely to
form the basic structure on the NIM metamaterials. Advanced methods of manufac-
turing, such as nanoscale lithography, selforganization of polymeric block structures,
or layer-by-layer deposition, which can also produce layers of NP and GNR separated
by a thin (1-2 nm) layer of polymer, are probably the most suitable approaches to
their manufacturing. Regardless of the method, bioconjugation processes provides a
universal method of attaching semiconductor NPs to the base metallic structure. (2)
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NPs present a natural advantage over the dyes for NIM materials with gain because
of much wider absorption spectrum which makes possible separation of pumping light
from the spectral window where NIM response can be observed.
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CHAPTER VIII
Field Induced Orientational Order of Gold
Nanorods Dispersed in Organic Solvents
8.1 Introduction
GNRs are promising building blocks of negative index metamaterials due to their
negative electric susceptibility at optical frequencies. There are two absorption peaks
in the optical response, associated with plasmon resonances for polarizations parallel
and perpendicular to the rod axis. Because the susceptibility at optical frequencies
is strongly anisotropic, a key requirement for realizing bulk optical negative index
materials is controlling orientational order. Low frequency electric fields may be
expected to align GNRs, however, such alignment is not at all straightforward, since
the susceptibility anisotropy at low frequencies far from resonance is small.
Previous work202 showed the alignment of long (aspect ratio >10) GNRs in aque-
ous solvents, where only the transverse absorption peak was in the visible spectrum.
Short (small aspect ratio) rods, where both plasmon resonances are in the visible, do
not align well in such systems, at least in part due to the large dielectric constant
of water at low frequencies. Organic solvents, with low dielectric constants overcome
this obstacle. Another reason for using organics as the suspension medium is the im-
proved stability against GNR aggregation. GNRs are solubilized in polar solvents by
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ionic surfactants. These also stabilize the suspension; their dissociation is responsible
for the electrostatic repulsion of particles. In such systems, the particles are in a sec-
ondary (local) energy minimum due to electrostatic interactions, and will eventually
aggregate since the global energy minimum occurs when the particles are in contact.
By contrast, metallic NPs can be solubilized in organic solvents by organic polymer
surfactants which can be covalently bonded to the surface of the GNRs. Such a sys-
tem is stabilized against aggregation by the entropic repulsion of the polymer chains,
and the system remains in the global free energy minimum indefinitely.
We have developed a novel method for dispersing GNRs in non-aqueous solvents.
This enables the production of NP suspensions which remain stable against aggrega-
tion indefinitely. The GNRs in these suspensions can be aligned by external electric
fields even if their aspect ratio is small (<3) and both plasmon resonances are in the
visible. Importantly, by controlling the aligning electric field, the alignment can be
varied as a function of time unlike other alignment methods proposed for alignment
of axial structures in organic matrixes.203,204 GNRs synthesized by wet chemistry are
limited to dispersion in water because the surfactant CTAB, essential for growth for
rods, is soluble in water only. Transfer of GNRs from aqueous to organic solvents
(phase transfer) has been achieved previously using water-immiscible ionic liquids
but this method is limited in its efficiency of phase transfer.205 The rods lose their
plasmon peaks and appear to aggregate after transfer into the organic solvent. Gold,
having high chemical affinity for thiol, seems to be the easiest choice for the replace-
ment of surfactants but presents its own challenges due to large Van der Waals forces
and the resulting agglomeration. Zubarev et al have used a slow and delicate process
for replacing the surfactant CTAB with polystyrene.206 Chen et al have reported
phase transfer from aqueous solvents to toluene using a combination of mercaptosuc-
cinic acid and tetraoctylammonium bromide.207 We introduce here a very simple and




8.2.1 Synthesis of GNRs
GNRs were synthesized using the method described in literature.57 Briefly, the
process involves reducing gold ions by a strong reducing agent (NaBH4) which then
form spherical NPs that act as a seed when added into a growth solution contain-
ing gold ions and the surfactant hexadecyltrimethyl ammonium bromide (CTAB).
Typically, seed solutions are made by mixing CTAB solution (5.0 mL, 0.20 M) with
HAuCl4 (5.0 mL of 0.0005 M) followed by the addition of ice-cold NaBH4 (0.6 ml,
0.010 M) under vigorous stirring for 2 minutes. The growth solutions are made by
adding AgNO3 (0.6 ml, 0.004 M) to CTAB solutions (10 mL, 0.2 M) followed by
addition of HAuCl4 (10 mL, 0.001M) and ascorbic acid (140 µL, 0.0788 M). To grow
rods, 24 µL of seed solution is added to the prepared growth solution and kept in a
water bath at 28 for 12 hours. The synthesized gold rods have bilayers of positively
charged surfactants on the surface and are dispersed in water. Excess stabilizer in
the solution is removed by centrifugation and redispersion of the rods in pure deion-
ized water. The process is repeated two times and 20 mL of synthesized rods are
concentrated into 1 mL of aqueous dispersion.
8.2.2 Phase transfer of GNRs into organic solvernts
To achieve dispersion in an organic solvent, we typically use a 5 mL glass vial in
which 1 mL of concentrated aqueous rod solution is added to 1 mL of polystyrene thiol
(55,000 mol. wt.) solution in tetrahydrofuran (THF) (25 mg/mL) and the mixture
is vigorously shaken by hand for 1 minute. The reaction leads to instantaneous
aggregation and the aggregates adhere to the glass wall, leaving behind colorless
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water and THF mixture. The aggregates have no specific shape or size. The water
and THF mixture is next decanted and the remaining moisture in the glass vial is
removed by drying with a heat gun (100  for 3 minutes). The gold rods inside the
aggregates have been grafted with polystyrene molecules and can be dispersed in any
on a wide variety of organic solvents(see Fig. 8.2(B)). Typically 1 mL of toluene is
added to the vial containing the aggregates and sonicated for 15 minutes to get a
homogeneous dispersion.
8.2.3 Field induced alignment of GNRs in organic solvent
Figure 8.1: Experimental geometry for homeotropic alignment
The experimental setup is shown in Fig. 8.1. A 0.35 mL, 1 mm path length,
cuvette containing the GNRs dispersed in toluene having 12.7×15.2 mm ITO coated
glass electrodes glued to the outside surface of the cuvette rather than inside the cu-
vette to prevent dielectric breakdown of the solvent and any ion issues. The cuvette
with electrodes is submersed into transformer oil (Clearco STO-50) to prevent ioniza-
tion of the air. The GNR solution is filled well above the height of the electrodes. A
15kV, 60Hz neon transformer (Franceformer 15030P) with a Variac is used to apply
an electric field on the GNR solution. The absorbance is measured with a spectrom-
eter (Oceanoptics HR4000CG-UV-NIR with Mikropack DH-2000 light source). For
the experiment we apply 15 kV across a 3 mm cuvette (1 mm path length), the max-
imum free space field is 5×106 [V/m]. By applying an electric field across the sample
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we orient the GNRs in a homeotropic alignment.
8.3 Results
8.3.1 Phase transfer of GNRs into organic solvernts
Figure 8.2: (A) Schematic of CTAB stabilized aqueous GNR. Red spheres indicate
positively charged head group (B) Schematic of polystyrene stabilized organic GNR.
White spheres indicate thiol head group. (C) UV-Vis absorption spectrum of GNRs
dispersed in various solvents (D) TEM images of GNRs dispersed in toluene
The choice of THF as a solvent for polystyrene thiol is critical for the reaction
because its solubility in water facilitates reaction between thiol molecules and the gold
atoms on the surface of rods. The nature of CTAB binding on the gold surface is
dynamic in nature, and the high affinity of sulfur groups for the gold causes immediate
covalent bonding of gold and polystyrene thiol. As the reaction proceeds towards
86
completion, the rods change from hydrophilic to hydrophobic and become insoluble in
the water and THF mixture which leads to their aggregation. Drying the aggregates
helps remove traces of THF which may be left behind. The aggregates dissolve
and redisperse into individual rods when introduced into an organic solvent. The
intermediate step of aggregation of rods does not in any way affect the shape or size
of the rods. The resulting dispersion shows both of the characteristic transverse and
longitudinal plasmon peaks in the absorption spectrum, with the same intensity as
in the aqueous solvent, but shifted due to change in the dielectric properties of the
surrounding fluid.207,208
8.3.2 Field induced alignment of GNRs in organic solvent
Figure 8.3: Experimental absorbance Vs. wavelength for changing applied electric
field
Fig. 8.3 is an absorbance spectrum for GNRs in toluene. The sample size of the
GNRs is approximately 40 nm × 15 nm and the volume fraction is, φ ≈ 10−5. The
transverse mode wavelength, λ‖, is at 525 nm and the longitudinal wavelength, λ⊥
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is at 659 nm. As the external electric field is increased we see suppression of the
longitudinal peak and a slight increase in the transverse peak as expected from the
previous studies of aligned GNR composites.209
Figure 8.4: Color change with field turned off (A) and turned on (B). Intesity change
with field turned off (C) and turned on (D)
A white light source (Mikropack DH-2000 light source) was shot through the
sample. We observe a drastic change in the apparent transmissive color when the
GNRs are oriented (Fig. 8.4 (A-B). The transmissive color appears to be blue in the
isotropic phase. When the field is applied, the longitudinal peak is suppressed, and
the transmissive color appears to be red. A Melles-Griot (25-LHP-925-249) 30 mW
HeNe laser is shot through the sample. In Fig. 8.4 (C-D) when the field is applied




The anisotropic susceptibility of GNRs is reponsible for the alignment of these
particles with an external electric field. The induced dipole moment of an inclusion
with dielectric constant and whose shape is an ellipsoid of revolution in a dielectric
host with dielectric constant, ε1, is given by,
pα = V ε0χαβEβ (8.1)



















where N‖ and N⊥ are the depolarizing factors for fields parallel and perpen-
dicular to the long axis of the ellipsoid.210 The frequency dependence of the dielectric





Here ωp is the plasma and β is the collision frequency. The energy of the inclusion







If the frequency of the applied field E is 60 Hz, ε2 is large and negative, and the
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where θ is the angle between E and the long axis of the ellipsoid. Since N‖ < N⊥ for
prolate ellipsoids, the GNRs tend to align with the field. In equilibrium, the degree



































If the length and width of a GNR are 40×15 nm and, assuming ellipsoidal shape,
N‖ = 0.125 and N⊥ = 0.438, and since for toluene ε1 ' 2.2, at T = 300K, Eq. 8.7
gives Ec = 1.94×106 V/m. Thus a large field, on the order of 1 V/µm, is required to
align the GNRs.
Two physical parameters must be taken into consideration regarding the externally
applied electric field. The first is the magnitude of electric field that must be applied
in order to get strong orientational alignment. The energy of the applied field must
be greater than the thermal energy fighting to disorient the GNR, i.e. ∆E2 > kT .
We can estimate the field strength assuming where ε0 is the permittivity of free







10−11×10−23 . We must apply
fields on the order of one million volts per meter before we can expect to see any
kind of alignment. The second is the reduction in electric field strength from the
depolarizing fields in the solvent. If we compare the relative electric field strength
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dielectric constant of water (aqueous) is 80.4 whereas toluene (non-aqueous) only has
a dielectric constant of 2.2. The large dielectric constant of water severally inhibits
the ability to experimentally achieve strong alignment of short aspect ratio GNRs.
The effective electric field in the suspension is reduced by a factor of 40 in water when
compared with toluene. It is then imperative to use a non-aqueous solvent, such as
toluene, for alignment in GNR suspensions.
Figure 8.5: Order paramater S as function of electric field strength
The two principal plasmon resonances from the GNR susceptibility tensor give rise
to two characteristic absorption peaks, the transverse mode wavelength, λ‖ and lon-
gitudinal mode wavelength, λ⊥, in the visible spectrum. We measure the absorbance,
αx, of a suspension of GNRs in a non-aqueous solvent as a function of electric field
strength (E2) with both plasmon resonances in the visible. The absorbance is linearly
proportional to the GNRs orientation. If an electric field is applied parallel to ~k, the
GNRs align with the field, we observe a suppression of the longitudinal peak absorp-
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tion as the field strength is increased (see Fig. 8.3). For the isotropic case, S=0, the
absorbance is at a maximum and when the GNRs are completely aligned, S=1, the
absorbance is at a minimum. Depending on the geometry of the external field we can
suppress one of the absorption peaks while isolating the complementary absorption
peak (see Fig. 8.3). We are able to achieve a high degree of alignment with an order
parameter of S≈0.9 (see Fig. 8.5)
8.5 Conclusions
Alignment of non-aqueous GNRs in solution was achieved with a maximum order
parameter of S≈0.9. A simple method for phase transfer of GNRs from aqueous to
non-aqueous solvent was developed. We developed a method to characterize the ori-
entational order of the system by measuring the absorbance versus externally applied
electric field. Due to the high degree of orientational order we observed transmissive
color and intensity changes in the GNR suspension.
92
CHAPTER IX
Real-Time Detection of Scrambled Prions on
3D-Supercrystals of Gold Nanorods
9.1 Introduction
Prions are hard-to-detect infectious agents that cause a number of fatal neurode-
generative diseases in mammalians such as bovine spongiform encephalopathy (BSE),
scrapie of sheep, and Creutzfeldt-Jakob Disease (CJD) of humans,213 and recently
traced as well to other neurodegenerative syndromes as Alzheimer214 and Parkin-
son.214 Invariably, all of these diseases involve the modification of the endogenous
and functional prion protein (PrPC) into a non-functional but much more stable form
(PrPSC) giving rise to the so-called amyloid plaques in the brain and other nervous
tissues.215 Notably, and in contrast with common infectious agents carrying a nu-
cleic acid genome, prions appear to encipher strain-specific properties in the tertiary
structure of PrPSC . The α-helix structure of the endogenous PrPC is refolded into
the β-sheet PrPSC through a post-translational process mediated by the PrPSC itself,
acting as a template, thus generating a chain reaction that leads to neurodegenera-
tion.216 The high stability of this new β-sheet conformation of PrPSC provides the
miss-folded proteins with unprecedented biological, chemical and physical resistance
toward for example proteases, nucleases, formaldehyde, UV light or temperature. All
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these features render PrPSC an extraordinary infectious agent as it can be transmit-
ted by ingestion of contaminated food (PrPSC resist conventional food sterilization
procedures without denaturation), or through contact with contaminated biofluids
such as saliva, urine or blood. On the other hand, because prions essentially are not
exogenous agents but endogenous proteins refolded into a non-functional structure,
they promote very weak or no immune responses. Thus, detection of its presence for
contention in cattle or diagnosis in humans is very difficult even by state-of-the-art
immunological methods such as FIA, RIA or ELISA.217 Thus the confirmation of BSE,
scrapie or CJD still relies on the post-mortem imaging analysis of the degenerated tis-
sues of the suspected individuals. This usually results in late response implying risk
of pandemic outbreak, with additional important economic consequences. Society
therefore urges for the development of novel detection techniques capable of accu-
rately detecting/diagnosing the presence of prions in the blood of infected but not
clinically sick animals to avoid the dissemination of the disease. Recent studies show
that the concentration of prions in infected presymptomatic individuals stays around
5 to 20 infective prion units per mL of blood (equivalent to the attomol regime) raising
to more than 100 in the early stages of the disease.218 This point is very important
as infected individuals and their fluids, including blood for transfusions,219,220 can
transmit the disease during pre-symptomatic stages, which, together with the long
latency of the syndrome (sometimes even years), makes prion detection critical to
avoid outbreaks.221
From the several approaches that have been developed for the pre-symptomatic
detection of prions in biofluids, only two, protein misfolding cyclic amplification
(PCMA)222 and immunological methods,223 have offered any promising results. How-
ever, PCMA analogously to PCR, relies on the conversion of the endogenous prion into
the scrambled entity, which for common detectors may take weeks, with subsequent
delays in achieving the results and increased risk of contagion for the laboratory
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personnel. Immunological methods, based on the recognition of prions by capture
and detection with specific antibodies also present severe drawbacks including the
cross reactivity of PrPC and PrPSC , which requires the digestion of the sample with
protease K, a process that may take several weeks, additionally increasing the uncer-
tainty of the final results. None of the prion detection schemes have resulted yet in
a method that allows fast, on-line monitoring of potentially contaminated products
prior to consumption. In this context, surface enhanced Raman scattering (SERS)
spectroscopy emerges as a viable alternative for the much needed direct detection
of PrPSC in biological fluids. SERS is not only one of the most sensitive analytical
techniques but also can be used under biological conditions, and it is extremely sensi-
tive to conformational changes in macromolecules such as proteins.224 Unfortunately,
SERS enhancement factors (EFs) obtained for conventional (non fluorescent) proteins
are still very low, ranging between 103 and 105, despite much higher EFs obtained for
highly aromatic molecules making possible even single molecule regimes of detection.
There are two additional very serious challenges as well. Both quantitative detection
by SERS and reproducible geometry of the “hot spot” necessary for SERS are difficult
to achieve. The way to solve these challenges is to design and fabricate a highly or-
ganized photonic structure225 that provides a high electromagnetic field enhancement
in a reproducible geometry.226,227 Recent demonstration of near field focalization by
nanoantennas228,229 has paved the way for development of ultrasensitive SERS sub-
strates which can concentrate the near field within certain confined regions allowing
one to obtain extremely high EFs.230–232 Such a nanoantenna effect was predicted
and found for nanorod (GNR) dimers, where the maximum focalization was found at
the GNR tips.233,234 One can hypothesize, therefore, that a highly organized system
of GNRs acting as an extended nanoantenna may yield the desired answers to the




Tetrachloroauric acid, silver nitrate, sodium borohydride, ascorbic acid, trisodium
citrate, hydrochloric acid, cetyltrimethyl ammonium bromide (CTAB), oleylamine
(OA, technical grade, 70%), chloroform (99%), ethanol (EtOH), benzenethiol (BT),
serum albumin (SA), phosphate buffered solution (PBS) solution, prion protein frag-
ment 106-126 (PrPC), prion protein fragment 106-126 scrambled (PrPSC) and bovine
serum were purchased from Sigma-Aldrich. 1Naphthalenethiol (1-NAT) was obtained
from Acros Organics. All chemicals were used as received. All glassware was washed
with aqua regia prior to the experiments. Milli-Q deionized water (resistivity >18
MΩcm−1) was used for all preparations.
9.2.2 Synthesis of monodisperse GNRs and supercrystals
Figure 9.1: (A)Photograph of one gram of isolated gold nanorods and (B) their TEM
image; (C) UV-vis absorption spectrum of NRs dispersion in water, used for the
preparation of the supercrysals
GNRs were prepared by a modification of the usual seeded-growth method. Specif-
ically, the growth solution was prepared by a two-fold increase in the concentration of
Au (III) ions, AgNO3, and ascorbic acid, whereas the amount of seed particles solu-
tion was increased from 12 µL to 9.6 mL as compared with the conventional method
(see Section 9.2.4). The presence of a slight excess of ascorbic acid (0.1 mol equiv.
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with respect to gold) promotes the growth of GNRs as soon as the seed solution is
added. The GNRs reach the size of 45 nm in length and 10 nm in width within 2
h, at which point the growth stops although there is still nearly 80 % of the initial
gold chloride present in solution. All these ions can be reduced and deposited onto
the surface of the GNRs if an additional amount of ascorbic acid (1.1 mol equiv) is
introduced at a very slow rate (0.001 mol equiv per hour). This slow process requires
nearly 100 h, but as long as the rate of reduction is kept at that level, all gold ions
are converted into metallic gold and deposited onto the original GNRs. The overall
amount of the isolated GNRs produced by this protocol is more than one gram (Fig.
9.1(A)). This process leads to an amplification of the NRs dimensions, which reach
75 nm in length and 25 nm in diameter. Most importantly, the yield of the reaction
becomes nearly quantitative (∼100 %) and the size distribution of NRs becomes much
narrower (σ ∼3%) as shown in Fig. 9.1(B). Due to their narrow size distribution the
GNRs have sharp peaks in the UV-vis absorption spectrum and (Fig. 9.1(C)) can
crystallize into 3D colloidal crystals when a drop of their aqueous suspension is cast on
a substrate and allowed to dry very slowly (7 days) in a saturated moist atmosphere.
9.2.3 Preparation of flexible gold ultra-long nanowire films for compari-
son of SERS effects
Figure 9.2: TEM images of the ultra-long rod nanowires at different magnifications
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In a typical synthesis, HAuCl4 (2.60 mg) was dissolved in OA (5 mL) by vor-
texing the mixture at room temperature until the solution turned from pale yellow,
the characteristic color of OA, to an intense orange color, which indicates complex
formation between Au3+ and OA. Thereafter, the solution was left undisturbed for 24
h, during which time the solution color changed again gradually from orange to pale
yellow, indicating the reduction of Au3+ to Au+. Next, the gold solution was aged for
5 days in a thermostatic bath at 35. Then, to 1 mL of this solution, 3 mL of CHCl3
and 3 mL ethanol were added. The solution was centrifuged at 5000 rpm for 20 min.
The supernatant was discarded and the precipitate redispersed in 3 mL CHCl3 . A
second centrifugation step (4000 rpm, 60 min) was carried out after the addition of
ethanol (3 mL), the supernatant was discarded and the precipitate redispersed in 3
mL CHCl3 (Fig. 9.2). Films were prepared by drop-casting and air-drying 10 µL of
the suspension on an ITO slide.
9.2.4 Preparation of gold nanorod films
Figure 9.3: TEM image of the “as prepared” rods used for comparison
A solution of gold seeds was prepared by borohydride reduction of HAuCl4 (0.25
mM, 5 mL) in aqueous CTAB solution (0.1 M). An aliquot of seed solution (24 µL)
was added to a growth solution (10 mL) containing CTAB (0.1 M), HAuCl4 (0.5
mM), ascorbic acid (0.8 mM), silver nitrate (0.12 mM) and HCl (19 mM). For the
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deposition of the gold nanorods on silicon wafers, 2 mL of the as prepared suspension
was centrifuged twice for 15 min, first at 6500 rpm and then at 4000 rpm. After
discarding the supernatant, the precipitate was redispersed finally in 1 or 0.25 mL of
water either to obtain non-aggregated particles (Fig. 9.3) or aggregated films made
of rods with predominantly parallel orientation, respectively, by spin-coating 10 µL of
the suspension on ITO slides. To prepare the fractal film of nanorods, the as prepared
suspension was centrifuged five times (6000 rpm, 15 minutes) and, after discarding the
supernatant, 10 µL of the precipitate, redispersed in 0.25 mL of water, was drop-cast
on a ITO slide.
9.2.5 Preparation of citrate reduced silver nanoparticle fractal films
Silver nanoparticles were reduced by adding 1 mL of trisodium citrate (1%) to
50 mL boiling solution of AgNO3 10
−3 M under stirring. The resulting solution was
centrifuged (6000 rpm, 15 min) and, after discarding the supernatant, 10 µL of the
precipitate was drop-cast on a ITO slide.
9.2.6 Characterization
TEM images were obtained using a JEOL JEM 1010 transmission electron micro-
scope operating at an acceleration voltage of 100 kV. Solid thin films were character-
ized using a field emission scanning electron microscope (FE-SEM, JEOL JSM-6700f).
Gold nanorod supercrystals were imaged and their scattering spectra acquired using
a 100 W halogen lamp illumination source on a Nikon Eclipse TE-2000 inverted op-
tical microscope coupled to a Nikon Dark-field Condenser (Dry, 0.95-0.80 NA). The
scattered light from selected supercrystal areas was collected with a Nikon Plan Fluor
ELWD 40×/0.60 NA objective and focused onto the entrance slit of a MicroSpec 2150i
imaging spectrometer coupled with a TE-cooled CCD camera (PIXIS 1024B ACTON
Princeton Instruments). The light scattered by the supercrystals was recorded in the
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dark-field microscope with collection times of 20 s. SERS experiments were conducted
with a micro-Raman Renishaw InVia Reflex system attached to a Leica microscope,
a 2-dimensional CCD camera and an automated stage with 100 nm spatial resolution.
The spectrograph used high-resolution gratings (1200 or 1800 g/mm) with additional
bandpass-filter optics. Several laser excitation energies were employed, including laser
lines at 633 (HeNe), 785 (diode) and 830 nm (diode). All measurements were made
in confocal mode in backscattering geometry using a 100×/0.90 NA objective which
provides a resolution of 500 nm. SERS maps were collected by using the Renishaw
StreamLine accessory with a step size of 500 nm.
In order to characterize the gold crystal rods films, BT was adsorbed in gas phase
over the whole surface of the films by casting a drop of BT (0.1 M in ethanol) in a
Petri box where the film was also contained. Surfaces were then mapped using the
Renishaw StreamLine accessory, taking mapping areas of 25×35 µm2, with a step-size
of 0.5 nm (1440 spectra each) upon excitation with three different laser lines: 633,
785 and 830 nm. Acquisition times were set to 200 ms with power at the sample
of 1 mW. For comparison, the same experiments (following the same protocol) were
carried out on the rest of the films (i.e. non-interacting GNRs, GNRs aggregated
parallel to each other, fractally aggregated GNRs, and fractally aggregated AgNPs).
Samples on ITO were cleaned with plasma previously to scanning electron microscopy
characterization and SERS analysis. In the case of the supercrystals, samples were as
well cleaned after the analyte exposure to check the efficiency in removing the organics
and the possibility of reusing the sample. Plasma was generated in a Solarus(Model
950) Advanced Plasma Cleaning System under the following conditions: 27.5 sccm
(standard cubic centimeters per minute) O2, 6.4 sccm H2, 70 mTorr and exposition
of 2 min.
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Figure 9.4: Effect of the plasma cleaning treatment. SERS mapping of BT adsorbed
onto a supercrystal film before (A) and after (B) the plasma treatment. As observed, a
substantial increase in the SERS intensity was obtained after cleaning mainly because
of the removal of all the stabilizing agents present on the gold surfaces. Notably, no
change in morphology of the supercrystal structure was observed. (λex: 785 nm;
StremLine maps carried out in confocal mode in backscattering geometry using a
100×/0.90 NA objective; acquisition time: 200 ms; power at the sample 1 mW;
step-size 500 nm)
9.2.7 Reusability of the supercrystal films
Material recyclability was tested by exposing the substrate to BT in gas phase,
cleaning the sample with the H2-O2 plasma (see above), and casting a dilute solution
of 1-NAT (10 µL, 10−4M). After each exposure, the sample was mapped with the
Renishaw StreamLine accessory (55×67 µm2, 500 nm step size with a total spectra
collection of 14310 points) with the 785 nm laser line in the same conditions as
described above. Mapping was carried out in two different spectral windows from BT
905 to 1190 cm−1 characteristic of BT and from 1670 to 1580 cm−1, characteristic
of 1-NAT. This procedure was repeated in several samples several times to ensure
reproducibility.
9.2.8 Prion detection
Stock solutions of PrPC and PrPSC 10−4 M were prepared in PBS (12 mM NaCl,
0.27 mM KCl and 1 mM phosphate buffer salts). From these, PrPSC solution was
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consistently diluted in PrPC solution (100, 50, 25, 10, 1 and 0% in PrPSC). Then,
10 mL samples of each solution were cast each onto a different supercrystal film and
studied with SERS (λex: 785 nm, 10s, 1 mW of power at the sample). Ten points were
collected for each sample to ensure reproducibility. This process was repeated as well
on a single crystal film, cleaning it with the plasma after each analysis, with similar
results. After setting the detection limit of PrPSC in PrPC to 1%, absolute detection
limits of PrPSC were determined by diluting the stock solution containing 1% of
PrPSC in 95% of PrPSC until concentrations of 10−11 M. SERS spectra were acquired
in the same conditions as described above. To probe the viability of this method to be
implemented in real samples with no need for any complicated separation protocol,
the same experiment was repeated using bovine serum as solution.
9.3 Results
We produced 75 nm × 25 nm (aspect ratio 3) GNRs on the basis of the seed-
mediated method.226,235 Modifications of the synthetic protocol resulted in improve-
ments of the resulting GNRs, which are quite significant: (1) a 1000-fold increase
in the amount of GNRs synthesized in one batch (Fig. 9.1) and, (2) very narrow
size distributions (∼ 3%). Consequently, GNRs were able to spontaneously and re-
producibly crystallize into three-dimensional (3D) colloidal crystals (supercrystals)
arranged as individual islands of fairly uniform dimensions (Fig. 9.5(A)) when the
aqueous GNR dispersions were slowly dried in humid atmosphere (Fig. 9.5). Both
the diameter (Fig. 9.5(B)) and height of individual GNR islands were in the range
of one micron, which corresponds to ∼15 layers of GNRs perpendicular to the sub-
strate. SEM examination revealed that the crystalline assemblies do not contain any
grain boundaries and the orientational and positional order of individual GNRs is
the same throughout the entire structure and from island to an island. The sepa-
ration between the adjacent GNRs is approximately 3 nm, which corresponds to a
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Figure 9.5: Nanorod supercrystals morphology. (A-C) SEM images corresponding to
different magnifications of a typical nanorod supercrystal island film. (D) View from
the edge of the supercrystal
bilayer of the cationic surfactant cetyltrimethyl-ammonium bromide (CTAB), and
has been described as the optimal separation between particles for the generation of
hot spots.236,237
The optical response of the supercrystals (Fig. 9.6(D)) was characterized using an
inverted dark field microscope. The localized surface plasmon resonance (LSPR) was
found to be very homogeneous throughout the entire surface and exhibits a maximum
at 696 nm. Electric near-field enhancement simulations of different rod supercrystals
support the hypothesis of the nanoantenna effect. Comparison of the simulations
for a three layer rod-stacked supercrystal (Fig. 9.6(E)) and a single rod monolayer
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Figure 9.6: Optical properties of the nanorod supercrystals. (A-C) Optical, SEM,
and dark field images of a GNR supercrystal, respectively, after plasma-etching re-
moval of surfactant coating of the GNRs. (D) Localized surface plasmon resonance
bands of the rods in solution (grey) and within a supercrystal, either at the center
(black) or at the edges (red). Dotted arrows indicate the excitation laser lines used
for SERS. (E-F), Electric field enhancement maps calculated for the top part of a
three layer rod-stacked supercrystal (E) and for the same location in a single mono-
layer (F). (G-J), SERS intensity maps corresponding to the supercrystal in fig. (A),
for BT as excited with a 633 nm (G), 785 nm (H) and 830 nm (I) laser lines, repre-
sentative SERS spectra for each laser being presented in (J). (K) Comparison of the
SERS intensities provided by a gold rod supercrystal (Au-RSC) film with common
SERS substrates including, aggregated ultra-long nanowires (Au-NW), single rods,
parallel and fractally aggregated gold GNRs (Single GNR, Parallel GNR and Fractal
GNR, respectively), and fractally aggregated silver nanoparticles (Fractal Ag-NP).
The intensity is the result of averaging over 50 different spots.
(Fig. 9.6(F)) indicate increased plasmon concentration on the top surface as layers
of rods are added. Note that the field intensity between the rods in the middle of the
stack is also very high (Fig. 9.7). The island morphology of the GNR film with tall
columns of supercrystals (Fig. 9.5(A,B))helps taking advantage of the interstitial hot
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Figure 9.7: Simulated electric field map in the cross-section of supercrystal. Electric
field map in the cross-section of the supercrystal at wavelengths (i) 428nm (ii) 750nm
and (iii) 1000nm. The field enhancement in the gaps between subsequent layers of
GNRs is clearly visible at the intermediate wavelength
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Figure 9.8: Simulated electric field intensity at various wavelengths in the cross-
section of the crystal
spots accessible for analytes from the solution as well. Characterization of the SERS
enhancing efficiency of GNR supercrystals was carried out in the same area, using
benzenethiol (BT). A highly homogeneous intensity was registered for three different
laser lines with an extremely high intensity for all of them, which is again consistent
with the electric field calculations as shown in Fig. 9.8. The monolayer of GNRs
have a very weak EF enhancement which is observed both theoretically (Fig. 9.8)
and experimentally (Fig. 9.6(K)). The CST MICROWAVE STUDIO simulations can
however include an error of upto 10% in the calculated electric fields due to limitations
on number of mesh cells which could not be increased further because of limited
computational capability. The electric field enhancements observed theoretically also
do not include the specific interactions between the analyte molecules and the metal
surface which can cause small deviations from the experimentally observed results.
Extensive comparative testing revealed that GNR supercrystals as SERS substrates
were largely superior to previously used arrangements of nanoparticles and GNRs,
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including single particle, and fractally aggregated or parallel GNRs (Fig. 9.6(K)).238
Additionally, islands of GNR supercrystals offer additional advantages for bioanalysis
compared to the best SERS substrates so far, i.e. fractal Ag films.
Figure 9.9: Reusability of supercrystals after plasma cleaning. SEM images and SERS
spectra and mapping of a supercrystal before and after cleaning the first analyte (BT)
and adding a different one (1-NAT)
They include higher chemical stability of gold over silver, reproducibility, and
highly homogeneous distribution of field intensity making possible quantitative SERS
detection of complex biomolecules. To that one might add as well mechanical stability
of the islands of the GNR supercrystal, which allows multiple use of the substrates
upon plasma etching of the previous analyte, which can be exemplified by SERS
analysis of BT and a second molecular probe (1-naphthalenethiol, 1-NAT) on the
same GNR crystal upon plasma etching of BT (Fig. 9.9). Notably, after cleaning,
no signal of BT was registered even when mapping a large area (30×30 µm2) while
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the morphology of the supercrystal remained unalterated and the SERS intensity was
still extremely high.
Figure 9.10: SERS spectra of PrPSC :PrPC mixtures (1:99) in decreasing concentra-
tion. Signal of the scrambled prion can be detected until concentration of total prion
of 10−12 M (10−12 M if considering the initial concentration of scrambled prion). (λex:
785 nm; StremLine maps carried out in confocal mode in backscattering geometry
using a 100×/0.90 NA objective; acquisition time: 10 s; power at the sample 1 mW).
The unique potential of these SERS substrates was thus exploited for the ultrasen-
sitive detection of scrambled prions within complex mixtures (natural serum). Due to
the high intrinsic toxicity of these materials and the requirement of a biosecurity lab
level 3 for their manipulation, we selected a model peptide (106-126, Fig. 9.11(A)),
widely used to investigate prion diseases239 as it forms fibrils in vitro and causes
apoptotic cell death in neuron culture. First, we investigated the SERS spectra of
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the biologically active and the scrambled prion in PBS. Then we studied the lower
proportion of PrPSC in PrPC that can be unambiguously determined. Because the
structures of both prions are very similar, so are their respective vibrational patterns
(Fig 9.10). SERS is dominated by a band at 762 cm−1 assigned to the interaction of
Au-S-C, and a triplet in PrPC (1390, 1416 and 1446 cm−1) which becomes a singlet
(1448 cm−1) in the scrambled version. These bands are related to the side chain bands
together with the amide II and III modes, especially in the -Met-Lys-His-Met- frag-
ment, responsible for the binding of the peptide to the gold surface. It is important
to bear in mind that, when prions are mixed, spectral patterns from the misfolded
prion are fully identifiable even when its relative concentration is as low as 1% that
of the normal prion. This is probably due to induction of the misfolding of PrPC
by PrPSC . On the other hand, by systematically diluting the mixture containing 1%
PrPSC and 99% PrPC we were able to detect scrambled prion signal down to a total
prion concentration of as low as 10−10 M. This is equivalent to 10 molecules per area
sampled, i.e. zeptomol regime (Fig. 9.10).
9.4 Conclusions
Such high sensitivity may make possible fast real-time detection of prions in a real
complex matrix, such as blood serum, which was never possible before.240 The SERS
spectrum of PrPSC :PrPC in serum (Fig. 9.11(E)) is dominated by bands correspond-
ing to the C-N stretching (1118 cm−1), Phe (1003, 1033 cm−1), Trp (1011 and 1560
cm−1), Tyr (845 cm−1) and Cys (720 cm−1). Upon sequential dilution of the prion
mixture (1% of PrPSC in 99% of PrPC) in serum, the characteristic prion bands can
still be clearly recognized down to concentrations as low as 10−10 M. The fact that
the prion proteins can be observed clearly identified in serum, a complex solution
containing high concentrations of proteins, mainly albumins but also globins, elec-
trolytes, antibodies, antigens, hormones, and any exogenous substances (e.g., drugs
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Figure 9.11: Scheme showing the prion mutation and detection limits for the scram-
bled version in bovine serum. (A) Biologically active (PrPC α-helix) and (B) scram-
bled (PrPSC β-sheet) prions; the fragment corresponding to 106-126 peptide is high-
lighted in green. SERS spectra of (C), PrPC α-helix) (D), PrPSC (scrambled) and
(E), bovine serum. (F-J), Detection limits of PrPSC :PrPC (1:99) in bovine serum, at
10−6, 10−7, 10−8, 10−9, and 10−10 M in total prion, respectively
and microorganisms) is likely to indicate the high affinity of prions for gold, which
is in agreement with the capacity of -Met-Lys-His-Met- groups present in prions to
efficiently chelate Au atoms.241
In summary, highly organized supercrystals of GNRs with plasmonic antennae en-
hancement of electrical field have made possible the first real-time detection of prions
in complex biological media such as serum. The particular nanoparticle morphology
and three-dimensional organization render these systems excellent SERS substrates
with uniform electric field enhancement, leading to both sensitive and reproducible
EFs in the desirable spectral range.
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CHAPTER X
Conclusions and Future Work
10.1 Summary of results
With intrinsic advantages including small sizes, ease of preparation and biocon-
jugation, unique optical properties, as well as good biocompatibility, GNRs have
been explored for potentially wide application in drug delivery, cellular imaging, and
biomedical diagnostics. This dissertation reports novel developments in the field of
targeted contrast agents for PAI as well as organization and self-assembly of GNRs for
application as SERS substrates and metamaterials. The following is a brief summary
of results.
Chapter II demonstrates the feasibility of photoacoustic imaging of inflammatory
responses using bioconjugated GNRs. To target the stimulated cells, GNRs were
conjugated to anti-intercellular adhesion molecule-1 (ICAM-1) which binds to cell
surfaces over expressing ICAM-1. A monolayer of stimulated endothelial cells labeled
with bioconjugated GNRs was scanned using a high frequency transducer. Photoa-
coustic images differentiated inflamed cells from control cells and matched well with
fluorescence images. This technology may permit identification of critical inflam-
mation sites such as blood vessels responsible for cardiovascular diseases. Chapter
III investigated the potential of photoacoustic imaging in noninvasive monitoring of
anti-TNF drug delivery. After the contrast agent composed of GNRs conjugated with
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Etanercept molecules was produced, ELISA experiments were performed to prove the
conjugation and to show that the conjugated anti-TNF-α drug was biologically ac-
tive. PAI of ex vivo rat tail joints with the joint connective tissue enhanced by
intra-articularly injected contrast agent was conducted to examine the performance
of PAT in visualizing the distribution of the gold-nanorod-conjugated drug in articular
tissues. By using the described system, GNRs with a concentration down to 1 pM in
phantoms or 10 pM in biological tissues can be imaged with good signal-to-noise ratio
and high spatial resolution. This study demonstrated the feasibility of conjugating
TNF antagonist pharmaceutical preparations with GNRs, preservation of the mech-
anism of action of TNF antagonist along with preliminary evaluation of novel PAI
technology in imaging optical contrast agents conjugated with anti-rheumatic drugs.
In future studies, PAI of drug delivery monitoring will be conducted on arthritic
animal models in vivo with systemic administration of drug-conjugated GNRs. We
expect that PAI enhanced by a novel gold nanoparticle contrast agent may contribute
considerably to the more efficient evaluation of drug effects in living laboratory ani-
mals and to optimize therapeutic decisions in human clinical practice in the future.
Many nanoparticle contrast agents have difficulties with deep tissue imaging. In
Chapter IV, we have investigated the potential of emerging photoacoustic imaging
and nuclear imaging in monitoring of anti-rheumatic drug delivery by using a newly
developed dual modality contrast agent. After the contrast agent composed of GNRs
conjugated to the anti-tumor necrosis factor (anti-TNF-α) drug Etanercept was pro-
duced, it was radiolabeled by 125I. ELISA experiments designed to test tumor necrosis
factor binding were performed to prove the specificity and biological activity of the
radiolabeled conjugated contrast agent. Photoacoustic and nuclear imaging were per-
formed to visualize the distribution of GNRs in articular tissues of the rat tail joints
in situ. Findings from the two imaging modalities corresponded well with each other
in all experiments. Our system can image GNRs down to a concentration of 10 pM
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in biological tissues and with a radioactive label of 5 µCi. This study demonstrates
the potential of combining photoacoustic and nuclear imaging modalities through
one targeted contrast agent for non-invasive monitoring of drug delivery. Chapter V
describes a novel technique to monitor in vivo behavior of GNRs using γ-imaging.
GNRs were radiolabeled using [125I] sodium iodide in a simple and fast manner with
high yield and without disturbing optical properties. Radiolabeled GNRs were suc-
cessfully visualized by the radioisotope tag, allowing longitudinal in vivo studies to
be performed repeatedly on the same animal. The preliminary biodistribution study
showed that Polyethylene glycol (PEG) GNRs have much longer blood circulation
times and clear out faster, while bare GNRs accumulate quickly in the liver after
systematic administration. The highly efficient method reported here provides an ex-
tensively useful tool for guidance of design and development of new gold nanoparticles
as target-specific agents for both diagnostics and photothermal therapy.
X-ray based computed tomography (CT) is among the most convenient imag-
ing/diagnostic tools in hospitals today in terms of availability, efficiency, and cost.
However, in contrast to magnetic resonance imaging (MRI) and various nuclear
medicine imaging modalities, CT is not considered a molecular imaging modality
since targeted and molecularly specific contrast agents have not yet been developed.
Chapter VI describes a targeted molecular imaging platform that enables, for the
first time, cancer detection at the cellular and molecular level with standard clinical
CT. The method is based on gold nanoprobes that selectively and sensitively target
tumor selective antigens while inducing distinct contrast in CT imaging (increased
X-ray attenuation). We present an in vitro proof of principle demonstration for head
and neck cancer, showing that the attenuation coefficient for the molecularly targeted
cells is over 5 times higher than for identical but untargeted cancer cells or for normal
cells. We expect this novel imaging tool to lead to significant improvements in cancer
therapy due to earlier detection, accurate staging, and microtumor identification.
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Apart from application as a contrast agent, gold nanorods due to their anisotropic
shape also form interesting building blocks for 3D superstructures with wide range of
optical properties for applications in plasmonics, metamaterials and sensors. GNRs
in different arrangements represent the most plausible system for the creation of
negative refractive index materials (NIMs) in the optical frequency range. Among
other challenges, one of the major limitations of present day NIMs is their large
amount of energy dissipation which frustrates the restoration of near field modes.
To take advantage of exciton-plasmon interactions, an optical system consisting of
semiconductor nanoparticles (NPs) and GNRs that can continuously pump energy
into the NIM resonator is described in Chapter VII. Superstructures with promising
properties were achieved by assembly of CdTe nanoparticles on the surface of nanorods
by using streptavidin-biotin bioconjugation where NP→GNR energy transfer occurs
with great efficiency. On the initial layer of bioconjugated NPs, the second layer
is formed due to nonspecific interactions, which is manifesting in unusual spectral
behavior and dependence of lifetime on NP concentration. By varying the ratio of
NPs per GNR, the amount of energy transfer can be controlled, while the diameter
of NPs and wide overlap offers the possibility to tune the wavelength of the pumping
light. Although the individual response of anisometric nanoparticles may be strongly
direction dependent, assemblies of randomly oriented GNRs are isotropic. To access
the full range of possible materials responses in dispersions, control over orientation
is required. GNRs can be oriented by electric fields, but if the dispersing medium is
aqueous, the alignment is poor unless the rods are very long. Chapter VIII describes
a simple novel technique for the phase transfer of aqueous GNRs to non-aqueous
solvents. It is demonstrated that in such solvents, a high degree of alignment (S≈ 0.9)
can be achieved by an external electric field even for short aspect ratio GNRs.
Fast in-situ detection of prion infections in biological samples of complex com-
position has numerous levels of difficulties stemming from their structural analogy
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to functional form of chemically identical peptides. This task has equally numerous
levels of significance both for public health and expansion of the boundaries of an-
alytical techniques. Surface enhanced Raman scattering (SERS) has the ability to
detect single aromatic molecules, but it has not proven successful so far in the case
of peptides, which would require purposeful design of SERS plasmonic substrates.
Chapter IX demonstrates that supercrystals of GNRs with nanoantenna effect en-
hancing electromagnetic field on the top of the supercrystal and highly reproducible
structure make possible real-time monitoring of prion presence in serum. Simulations
by CST MICROWAVE STUDIO confirm the nanoantenna effect and large electric
field enhancements.
10.2 Future research directions
10.2.1 Simultaneous PAI of multiple inflammatory biomarkers
Understanding and monitoring the bioactivity of the inflammatory responses will
provide prognostic information of the major systemic diseases such as atherosclerosis.
Some inflammatory biomarkers have predictive value for future vascular events. Mul-
tiple targeting of different biomarkers using GNRs of different aspect ratios for optical
absorption centered at different wavelength will enable simultaneous detection of dif-
ferent inflammatory responses. Preliminary in vitro cell experiments demonstrate the
feasibility to detect the over expressions of ICAM-1 and E-selectin simultaneously by
photoacoustics.
10.2.1.1 Preliminary results
HUVECs were cultured on gelatin-coated glass slides, and inflammation was in-
duced by IFN-γ and TNF-α. At 0, 2, 6, 24 hrs after the stimulation, slides ex-
posed to GNRs 800 nm -conjugated FITC labeled anti-ICAM-1 or GNRs 800 nm-
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Figure 10.1: Bright field (A-D & M-P), Fluorescent (E-H & Q-T), and Photoacoustic
(I-L & U-X) images for both ICAM targeted imaging (left panels) and E-Selectin
(right panels) at various time points
conjugated biotinylated anti-E-Selectin. The expression of each biomarker was visu-
alized by direct fluorescence imaging of the FITC label or fluorescent imaging using
PE-streptavidin. Expression was also quantified by rt-PCR. For Photoacoustic (PA)
scanning, the top surface of the cell culturing slide was illuminated by a pulsed laser
beam at 800 nm (Nd:YAG, 5 ns, 10 Hz, 4 mJ/cm2). A high frequency ultrasonic
transducer (60 MHz) connected to a motorized X-Y stage was used to scan the PA
signal over the area of 200 µm by 200 µm with 10 µm step size. Fig. 10.1 illustrates
the corresponding bright field (A-D & M-P), fluorescent (E-H & Q-T), and PA (I-L
& U-X) images for both ICAM targeted imaging (left panels) and E-Selectin (right
panels) at various time points. Overall PA signal intensity level is comparable to
fluorescence image intensity at these time points. rt-PCR confirms the up-regulation
of mRNA similar levels along this time course. It is demonstrated that PAI using bio-
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conjugated GNR as targeted contrast agent can detect and monitor the up-regulation
of ICAM-1 or E-selectin simultaneously in HUVECs. Future work would involve si-
multaneous targeting of several biomarkers and studying the in vivo behavior of the
targeted contrast agents. Simultaneous targeting could also prove useful in scanning
patients for various kinds of cancer cells in body through a single dose of contrast
agent.
10.2.2 Chiral nanocomposites
Figure 10.2: Schematic of chiral nanocomposite from LBL films
Negative Index Materials (NIMs) because of their ability to refract light on the
opposite side of the normal have the most intriguing optical properties which may
find application in construction of perfect lens and cloaking devices. The two most
actively pursued approaches to NIMs are via using resonating metallic nanostructures
and photonic crystals. Recent theoretical investigations have showed that NIMs can
also be realized through chiral materials if the chirality is sufficiently strong. The
current work is an effort to realize chiral negative index materials by using resonating
metallic nanorods in polymers to create highly chiral nanocomposites. Anisotropic
gold nanorods are aligned inside stretched thin polymer films to create strong po-
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larizers owing to the LPR. The stretched films are then piled on at a rotating angle
and hot pressed into one composite film (Fig. 10.2). The dependence of chirality
on the concentration of gold nanorods, piling angle and thickness of the composite
need to be invstigated. One of the biggest advantages of this system is that a chiraly
active material can be achieved over a large range of wavelength simply by tuning
the absorption of the rods.
10.2.2.1 Preliminary results
Figure 10.3: (A) UV-Vis absorption of PU and PU+GNRs dipersion. (B) CD spec-
trum of polymer dispersions. (C) CD spectrum of single stretched films (D) CD
spectrum of chiral nanocomposites
Cationic Polyurethane (PU) films are nearly transparent and have excellent me-
chanical properties. Previous reports from our group have showed that PU films are
capable of withstanding high strain values242,243 which is a highly desirable prop-
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erty to align GNRs via stretching.209,244 Initial experiments with bulk polyurethane
(PU) doped with GNRs provided encouraging results. Stretched PU films doped with
GNRs were affixed on polycarbonate substrate and stacked on top of each other at
various angles. The substrate is placed under a hot press at 100  and 7 MPa pres-
sure for 5 hours to produce the chiral nanocomposite. It was observed that single
stretched films of PU, PU+NP and PU+GNRs have nearly zero circular dichorism
(CD). However the nanocomposite from stretched films have strong chiral signal at
500 nm corresponding to the transverse plasmon peak and the second peak corre-
sponding to the stronger longitudinal plasmon does not appear due to saturation of
the photodetector in CD machine. The signal is also dependent on the angle at which
the films are stacked (Fig. 10.3(D)). It is to be noted that CD signal from stretched
films is a sum of linear dichorism (LD), linear birefringence (LB), circular dichorism
and circular birefringence (CB).245,246
Figure 10.4: Schematic of the setup for measuring rotation in polarization
Due to the presence of single photodetector in a standard CD machine it is difficult
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to find the individual contributions of LD, LB and CB which may be contributing
a lot to the overall signal. In order to overcome this problem a setup shown in Fig.
10.4 was designed to evaluate the rotation in polarization of light from the chiral
nanocomposites. The beam from Ti:S laser is passed through a set of neutral density
filters to reduce the peak power and either a half-wave plate or quarter wave plate is
used to generate linear or circularly polarized light. After the incoming beam passes
through the sample, a beam splitter is placed in the path to separate light into linear
components which are measured at respective detectors connected to an oscilloscope.
Figure 10.5: (A-C) SEM image of polyurethane GNR exponential LBL film. (D)
Optical photograph of free standing LBL film. (E-F) SEM image of the cross-section
of LBL film
Also due to the requirement of thin films for stronger effective chirality of a
medium it was imperative to build films by Layer-by-Layer (LBL) technique in-
stead of curing bulk PU+GNRs dispersion. Exponential LBL films were made using
(PU/PAA/GNR/PAA)n where the concentration of PU and dipping time in GNRs
solution was optimized to obtain films with high loading of GNRs and high strain
bearing capacity (Fig. 10.5). The ellipsometric measurements showed that the growth
120
Figure 10.6: (A) Ellipsometric measurements on LBL film (B) UV-Vis absorption
of LBL films made under different experimental conditions (C) Thermogravimetric
Analysis of LBL films made under different experimental conditions.
of film is exponential (Fig. 10.6(A)) and it was measured by SEM to be 11 µm after
40 quadlayers. The UV-Vis data suggested that at lower PU dilutions the loading of
GNRs is poor and at higher dilutions the plasmons of GNRs get broadened possibly
due to higher loading of GNRs (Fig. 10.6(B)). Thermo gravimetric analysis (Fig.
10.6(C)) showed that the metal content in the film is about 2 wt% and the most
optimum dipping time in GNR solution is 2mins.
Future work involves in depth optical characterization of the chiral nanocompos-
ites made from LBL thin films using the setup described in Fig. 10.4. The setup
under certain limitations will help uncouple the contribution of LD, LB and CB
to the overall CD signal. It will be interesting to explore and investigate different
polymer systems. In order to achieve strong chirality necessary for NIMs it might
be required to further decrease the thickness of films while retaining the mechanical
properties. Metallic losses due to operation near resonance will be among the many
challenges to realize optical NIMs through chirality, which will require potential gain
materials similar to those described in Chapter VII.
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